var title_f40_23_41328="Epinephrine (adrenaline): Patient drug information";
var content_f40_23_41328=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Epinephrine (adrenaline): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/59/4020?source=see_link\">",
"       Epinephrine (adrenaline) (nasal): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/24/10630?source=see_link\">",
"       Epinephrine (adrenaline) (systemic therapy and oral inhalation): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11638 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_23_41328=[""].join("\n");
var outline_f40_23_41328=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/59/4020?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/24/10630?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_23_41329="Aorta anatomy PI";
var content_f40_23_41329=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F74006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F74006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Anatomy of the aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 489px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The aorta is the main artery that delivers blood from the heart to the body. The aorta travels through the chest (thoracic aorta) and the abdomen (abdominal aorta).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_23_41329=[""].join("\n");
var outline_f40_23_41329=null;
var title_f40_23_41330="Insertion of cube pessary";
var content_f40_23_41330=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cube vaginal pessary in position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Milex Products, Inc., Chicago, IL.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_23_41330=[""].join("\n");
var outline_f40_23_41330=null;
var title_f40_23_41331="Trientine: Patient drug information";
var content_f40_23_41331=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Trientine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/46/14052?source=see_link\">",
"     see \"Trientine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Syprine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Syprine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692133",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Wilson's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703079",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to trientine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697168",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have anemia, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696874",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take dairy products, bismuth (Pepto-Bismol&reg;), calcium, iron, magnesium, zinc, multivitamins with minerals, colestipol, cholestyramine, didanosine, or antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11435 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-1F4CD360AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_23_41331=[""].join("\n");
var outline_f40_23_41331=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230917\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230918\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031403\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031402\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031407\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031408\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031410\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031405\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031406\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031411\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031412\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?13/46/14052?source=related_link\">",
"      Trientine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_23_41332="Histopathology and molecular pathogenesis of medulloblastoma";
var content_f40_23_41332=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Histopathology and molecular pathogenesis of medulloblastoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/23/41332/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/23/41332/contributors\">",
"     Scott L Pomeroy, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/23/41332/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/23/41332/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/23/41332/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/23/41332/contributors\">",
"     Amar Gajjar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/23/41332/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/23/41332/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/23/41332/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medulloblastomas are the most common malignant brain tumor of childhood and occur exclusively in the cerebellum. The disease is rare after the fourth decade of life.",
"   </p>",
"   <p>",
"    The histopathology and molecular pathogenesis of medulloblastoma will be reviewed here. The clinical presentation, diagnosis, and treatment of medulloblastoma in children and adults, its prognosis, and the delayed complications in survivors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/0/2058?source=see_link\">",
"     \"Epidemiology, treatment, and prognosis of medulloblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;At surgery, medulloblastomas are soft, friable tumors, often with necrosis. They are highly cellular tumors with abundant dark staining, round or oval nuclei, and little cytoplasmic differentiation. The spectrum of histopathologic appearance ranges from tumors with extensive nodularity to those with large",
"    <span class=\"nowrap\">",
"     cell/anaplastic",
"    </span>",
"    features. The clinical outcome appears to be worse with increasing grade and extent of anaplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/1\">",
"     1",
"    </a>",
"    ]. Mitoses are often abundant, and neuroblastic Homer Wright rosettes can be found in up to 40 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunohistochemical studies most often demonstrate the expression of the neuronal markers synaptophysin and neuron specific enolase, and nestin, a marker of primitive neuroepithelial cells, consistent with their presumed origin from neuronal progenitors in the cerebellum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/4\">",
"     4",
"    </a>",
"    ]. A majority of medulloblastomas also express markers specific for cerebellar granule cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], supporting the conclusion that they arise most often by oncogenic transformation of cerebellar granule cells. Consistent with this hypothesis is the observation that favorable medulloblastomas express high levels of the neurotrophin-3 receptor, TrkC, which is a marker of mature forms of granule cells in the developing cerebellum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/7\">",
"     7",
"    </a>",
"    ]. TrkC expression correlates with prognosis in most but not all studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/0/2058?source=see_link&amp;anchor=H29#H29\">",
"     \"Epidemiology, treatment, and prognosis of medulloblastoma\", section on 'Prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several variants of medulloblastoma have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/8\">",
"     8",
"    </a>",
"    ]. A desmoplastic variant of medulloblastoma has been described, with abundant collagen and reticulin in the interstitial spaces as well as reticulin free \"pale islands\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/3\">",
"     3",
"    </a>",
"    ]. This variant is associated with mutations in the patched (PTCH) gene on chromosome 9 and may have a better prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/9\">",
"     9",
"    </a>",
"    ]. A second variant, the large cell anaplastic medulloblastoma, is characterized by cerebrospinal fluid dissemination and a more aggressive clinical course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/10\">",
"     10",
"    </a>",
"    ]. The prognostic implications of these variants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/0/2058?source=see_link&amp;anchor=H29#H29\">",
"     \"Epidemiology, treatment, and prognosis of medulloblastoma\", section on 'Prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously, medulloblastomas were thought to represent a subset of primitive neuroectodermal tumor (PNET) of the posterior fossa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/11\">",
"     11",
"    </a>",
"    ]. However, gene expression profiling has shown that medulloblastomas have a distinct molecular profile and are distinct from other PNET tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Available data suggest that medulloblastomas arise from granule cell progenitors or from multipotent progenitors from the ventricular zone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Progression to medulloblastoma is thought to occur when these granule cell progenitors are subject to continued stimulation or there is a failure of these cells to exit the cell cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetic predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 2 to 5 percent of children with medulloblastomas have inherited disorders with germline mutations of specific genes that predispose to the development of medulloblastoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. An understanding of the molecular pathways involved in these genetic syndromes has provided insights into the pathogenesis of sporadic medulloblastomas as well.",
"   </p>",
"   <p>",
"    The Gorlin syndrome is the most common of these inherited disorders, and is due to mutations in the patched-1 (PTCH-1) gene, a key component in the sonic hedgehog (SHH) pathway. Turcot's syndrome is linked to mutations in the adenomatous polyposis coli (APC) gene and familial adenomatous polyposis, which has also been associated with an increased incidence of medulloblastoma. Studies of patients with Turcot's syndrome have led to recognition of the role of the Wingless (WNT) pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     SHH pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The granule cell progenitors can be stimulated to proliferate by the cerebellar Purkinje cells in a process that is mediated by SHH protein. Overactive signaling by SHH appears to have a proliferative effect on these cells and thus contributes to the pathogenesis of medulloblastoma in at least two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SHH binds to its receptor Patched 1 (PTCH1). In the absence of binding to SHH, PTCH1 normally interacts with Smoothened (SMO), blocking the downstream activation of a number of downstream transcription pathways. Overactive signaling by SHH prevents the inhibition of these pathways by PTCH1 (",
"      <a class=\"graphic graphic_figure graphicRef69105 \" href=\"mobipreview.htm?13/37/13904\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      SHH appears to upregulate the N Myc gene. N Myc has multiple effects in the cell cycle, and degradation of N Myc appears necessary for the granule cell progenitors to exit the cell cycle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of the SHH pathway in the pathogenesis of medulloblastoma was originally described in patients with Gorlin syndrome (also called nevoid basal cell carcinoma syndrome or basal cell cancer syndrome). The clinical manifestations of Gorlin syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/5/44121?source=see_link\">",
"     \"Nevoid basal cell carcinoma syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gorlin syndrome is an autosomal dominant disease due to germline mutations of the human PTCH1 gene on chromosome 9. Later in life, medulloblastomas develop in 3 to 5 percent of these individuals, typically the desmoplastic type. Other malignancies including multiple basal cell cancers and meningiomas.",
"   </p>",
"   <p>",
"    Activation of the SHH pathway can occur in the absence of mutations to PTCH1 in patients with medulloblastoma. These include truncating mutations of PTCH2, a homologue of PTCH1 that is localized to the short arm of chromosome 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/17\">",
"     17",
"    </a>",
"    ], both somatic and germline mutations in the Suppressor of Fused (SUFU), another gene involved in the SHH pathway that is localized to chromosome 10q [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/18\">",
"     18",
"    </a>",
"    ], and mutations in GLI3, a downstream component of the SHH pathway, located on chromosome 7p [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/19\">",
"     19",
"    </a>",
"    ]. As in the Gorlin syndrome, these medulloblastomas are often desmoplastic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     WNT pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;WNT signaling mutations have been identified in approximately 15 percent of patients with sporadic medulloblastomas. The WNT protein binds to its receptor, Frizzled, and this interaction destabilizes a multiprotein complex that includes the adenomatous polyposis coli (APC) protein. This in turn initiates a sequence of events that can activate various transcription factors, which are important in the pathogenesis of medulloblastoma.",
"   </p>",
"   <p>",
"    Turcot's syndrome refers to an association between brain tumors (primarily medulloblastomas and gliomas) and two different forms of inherited colonic polyposis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/20\">",
"     20",
"    </a>",
"    ]. Familial adenomatous polyposis (FAP) is an autosomal dominant condition caused by a mutation in the APC gene on chromosome 5. The majority of FAP-associated brain tumors are medulloblastomas, but gliomas have also been described. In contrast, in families with HNPCC, only gliomas have been described, not medulloblastomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17016?source=see_link&amp;anchor=H625428197#H625428197\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\", section on 'Turcot's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of medulloblastoma in patients with FAP appears to be highest in those with mutations in segment 2 of the APC gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/21\">",
"     21",
"    </a>",
"    ]. If this observation is confirmed, patients with mutations in this portion of the APC gene might be candidates for genetic counseling or surveillance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic regulation of metastatic behavior",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medulloblastomas have a tendency to disseminate throughout the central nervous system early in the course of the disease, and metastatic disease is associated with a poor outcome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/0/2058?source=see_link\">",
"     \"Epidemiology, treatment, and prognosis of medulloblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    New molecular insights suggest genetic regulation of metastatic behavior. In one report of 23 primary medulloblastomas, of which ten were metastatic and 13 nonmetastatic, the platelet-derived growth factor receptor alpha (PDGFR-a) was upregulated and overexpressed in the metastatic tumors and associated with migratory behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41332/abstract/22\">",
"     22",
"    </a>",
"    ]. Cell culture experiments with medulloblastoma cell lines demonstrated that overexpression of PDGFR-a increased the phosphorylation and upregulation of downstream",
"    <span class=\"nowrap\">",
"     RAS/mitogen-activated",
"    </span>",
"    protein (MAP) kinase signal transduction pathways, while inhibition of these MAP kinases prevented PDGFR-a-stimulated migration in a cell culture assay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medulloblastomas are highly cellular tumors presumed to arise from neuronal precursors in the cerebellum. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In about 5 percent of cases, medulloblastomas have been associated with one of two inherited disorders that are providing insight into the molecular pathogenesis of these tumors. An understanding of these pathways may eventually facilitate targeted therapy in patients with these tumors. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Genetic predisposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The Gorlin syndrome is due to mutations in the patched-1 (PTCH-1) gene, which is a key component in the sonic hedgehog pathway. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'SHH pathway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In Turcot's syndrome, medulloblastomas are seen in conjunction with colonic polyposis. This syndrome is associated with mutations in the WNT pathway. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'WNT pathway'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/1\">",
"      Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002; 94:552.",
"     </a>",
"    </li>",
"    <li>",
"     Kleihues, P, Burger, PC, Scheithauer, BW. Histological Typing of Tumours of the Central Nervous System. Springer-Verlag, Berlin, 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/3\">",
"      Katsetos CD, Liu HM, Zacks SI. Immunohistochemical and ultrastructural observations on Homer Wright (neuroblastic) rosettes and the \"pale islands\" of human cerebellar medulloblastomas. Hum Pathol 1988; 19:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/4\">",
"      McLendon RE, Friedman HS, Fuchs HE, et al. Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study. Histopathology 1999; 34:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/5\">",
"      Kozmik Z, Sure U, R&uuml;edi D, et al. Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci U S A 1995; 92:5709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/6\">",
"      Yokota N, Aruga J, Takai S, et al. Predominant expression of human zic in cerebellar granule cell lineage and medulloblastoma. Cancer Res 1996; 56:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/7\">",
"      Kim JY, Sutton ME, Lu DJ, et al. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res 1999; 59:711.",
"     </a>",
"    </li>",
"    <li>",
"     Giangaspero, F, Eberhart, CG, Haapasalo, H, et, al.. Medulloblastoma. In: WHO Classification of Tumours of the Central Nervous System, 4th, Louis, DN, Ohgaki, H, Wiestler, OD, Cavenee, WK. (Eds), IARC, Lyon 2007. p.132.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/9\">",
"      Sure U, Berghorn WJ, Bertalanffy H, et al. Staging, scoring and grading of medulloblastoma. A postoperative prognosis predicting system based on the cases of a single institute. Acta Neurochir (Wien) 1995; 132:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/10\">",
"      Leonard JR, Cai DX, Rivet DJ, et al. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. J Neurosurg 2001; 95:82.",
"     </a>",
"    </li>",
"    <li>",
"     Bigner, DD, McLendon, RE, Bruner, JM. Russell and Rubenstein's Pathology of Tumors of the Nervous System, Arnold, London, 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/12\">",
"      Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002; 415:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/13\">",
"      Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 2007; 4:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/14\">",
"      Oliver TG, Wechsler-Reya RJ. Getting at the root and stem of brain tumors. Neuron 2004; 42:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/15\">",
"      Evans G, Burnell L, Campbell R, et al. Congenital anomalies and genetic syndromes in 173 cases of medulloblastoma. Med Pediatr Oncol 1993; 21:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/16\">",
"      Evans DG, Farndon PA, Burnell LD, et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br J Cancer 1991; 64:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/17\">",
"      Smyth I, Narang MA, Evans T, et al. Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Hum Mol Genet 1999; 8:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/18\">",
"      Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002; 31:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/19\">",
"      Erez A, Ilan T, Amariglio N, et al. GLI3 is not mutated commonly in sporadic medulloblastomas. Cancer 2002; 95:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/20\">",
"      Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995; 332:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/21\">",
"      Attard TM, Giglio P, Koppula S, et al. Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis. Cancer 2007; 109:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41332/abstract/22\">",
"      MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001; 29:143.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5218 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-C3CD4DCF74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_23_41332=[""].join("\n");
var outline_f40_23_41332=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetic predisposition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - SHH pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - WNT pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic regulation of metastatic behavior",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5218\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5218|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/37/13904\" title=\"figure 1\">",
"      Shh Gli pathway medulloblastoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/0/2058?source=related_link\">",
"      Epidemiology, treatment, and prognosis of medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/5/44121?source=related_link\">",
"      Nevoid basal cell carcinoma syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_23_41333="Aluminum hydroxide and magnesium trisilicate: Drug information";
var content_f40_23_41333=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aluminum hydroxide and magnesium trisilicate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/26/9636?source=see_link\">",
"    see \"Aluminum hydroxide and magnesium trisilicate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gaviscon&reg; Tablet [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F132629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antacid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F132623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dyspepsia, gastric acidity: Oral: Chew 2-4 tablets 4 times/day or as directed by healthcare provider",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F132624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F132625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aluminum and/or magnesium may accumulate in renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable: Aluminum hydroxide 80 mg and magnesium trisilicate 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gaviscon&reg;: Aluminum hydroxide 80 mg and magnesium trisilicate 20 mg [contains sodium 0.8 mEq/tablet; butterscotch flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F132617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets should be chewed and not swallowed whole. Administer 1-3 hours after meals with water, milk, or juice.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F132616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of hyperacidity",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Antacids may decrease the absorption of Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Antacids may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction. Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Aluminum Hydroxide may decrease the serum concentration of Chenodiol.  Management: Consider administration of chenodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citric Acid Derivatives: May increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Aluminum Hydroxide may diminish the therapeutic effect of Deferasirox.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Aluminum Hydroxide may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., aluminum-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethambutol: Aluminum Hydroxide may decrease the absorption of Ethambutol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Antacids may decrease the serum concentration of Fexofenadine.  Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Aluminum Hydroxide may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and aluminum hydroxide by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Misoprostol: Antacids may enhance the adverse/toxic effect of Misoprostol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea.  Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Aluminum Hydroxide. Management: In patients with severe renal dysfunction, consider avoiding this combination of agents.  Administering agents at least 2 hours apart may help minimize the interaction(s).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitrofurantoin: Magnesium Trisilicate may decrease the serum concentration of Nitrofurantoin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antacids may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Antacids may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Antacids may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of SPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction. Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Aluminum Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and aluminum hydroxide by at least 2 hours whenever possible in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Aluminum Hydroxide may decrease the serum concentration of Ursodiol.  Management: Consider administration of ursodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14286998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most aluminum-containing antacids are considered low risk during pregnancy; however, use of antacids containing magnesium trisilicate should be avoided (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14286999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most aluminum-containing antacids are considered low risk in nursing women (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F132619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken 1-3 hours after meals with water, milk, or juice. Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Gaviscon Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80-14.2 mg (30): $2.75",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12707669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Maalox (TH)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U and Kane S, \"American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 131(1):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/23/41333/abstract-text/16831610/pubmed\" id=\"16831610\" target=\"_blank\">",
"        16831610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8615 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-F2EAE850DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_23_41333=[""].join("\n");
var outline_f40_23_41333=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132621\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132629\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132623\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132624\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132625\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132615\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132606\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132617\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132616\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298724\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132611\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286998\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286999\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132619\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322979\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12707669\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8615\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8615|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/26/9636?source=related_link\">",
"      Aluminum hydroxide and magnesium trisilicate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_23_41334="Treatment of erythema multiforme";
var content_f40_23_41334=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of erythema multiforme",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/23/41334/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/23/41334/contributors\">",
"     David A Wetter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/23/41334/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/23/41334/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/23/41334/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/23/41334/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/23/41334/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythema multiforme (EM) is an acute, immune-mediated condition characterized by the appearance of distinctive target-like lesions on the skin. These lesions are often accompanied by erosions or bullae involving the oral, genital,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ocular mucosae (",
"    <a class=\"graphic graphic_picture graphicRef68640 graphicRef79955 graphicRef62370 graphicRef65570 graphicRef58969 graphicRef75314 \" href=\"mobipreview.htm?43/8/44170\">",
"     picture 1A-F",
"    </a>",
"    ). Erythema multiforme major is the term used to describe EM with mucosal involvement; erythema multiforme minor refers to EM without mucosal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37672?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of factors have been implicated in the pathogenesis of EM. The disorder is most commonly induced by infection, with herpes simplex virus being the most frequent precipitator. The clinical course of EM is usually self-limited, resolving within weeks without significant sequelae. However, in a minority of cases, the disease recurs frequently over the course of years.",
"   </p>",
"   <p>",
"    Similarities in clinical and histopathologic findings have led to controversy over the distinction between EM and Stevens-Johnson syndrome (SJS), an often drug-induced disorder that may present with cutaneous targetoid lesions and mucosal erosions. However, there is suggestive evidence that EM with mucous membrane involvement and SJS are different diseases with distinct causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/1\">",
"     1",
"    </a>",
"    ]. The term erythema multiforme major should",
"    <strong>",
"     not",
"    </strong>",
"    be used to refer to SJS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link&amp;anchor=H25#H25\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\", section on 'Nosologic controversies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment and prognosis of acute and recurrent EM will be reviewed here. The epidemiology, pathogenesis, clinical features, evaluation, and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37672?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT OF ACUTE EM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of acute erythema multiforme (EM) varies according to disease severity. The clinical course of an episode of EM is self-limited, although the disease may recur. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Prevention of recurrent EM'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Interventions targeted toward reducing pain or pruritus are sufficient for patients with mild disease. In contrast, systemic glucocorticoid therapy should be considered for patients with severe oral mucosal involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Inciting agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 90 percent of cases of EM are triggered by infections, but there are few data on the effect of acute treatment of the inciting infection on the severity or duration of EM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37672?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Herpes simplex virus (HSV)-induced EM occurs an average of eight days after the development of HSV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/2\">",
"     2",
"    </a>",
"    ], at a time when treatment solely for HSV infection is no longer indicated. The results of two case series suggest that treatment with oral antivirals after the appearance of HSV-associated EM does",
"    <strong>",
"     not",
"    </strong>",
"    affect the clinical course of the eruption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no formal studies of the effect of treatment of other infectious causes of EM, such as Mycoplasma pneumoniae, on the duration or severity of mucocutaneous lesions. In general, treatment should be instituted as appropriate for management of an active infection. If EM is thought to be due to a new drug, the drug should be discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mild disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with only cutaneous involvement or limited oral mucosal involvement that is not disabling, management is focused on symptomatic relief. Topical corticosteroids (medium potency, low potency for facial or intertriginous areas) and oral antihistamines can be used in patients who note itching and burning of cutaneous lesions (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Painful oral erosions can be treated with a high potency topical corticosteroid gel and mouthwashes that contain a mixture of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , and antacids. We typically use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/56/30596?source=see_link\">",
"     fluocinonide",
"    </a>",
"    0.05% gel applied two to three times per day, and a mouthwash containing equal parts of viscous lidocaine 2%, diphenhydramine (12.5",
"    <span class=\"nowrap\">",
"     mg/5",
"    </span>",
"    mL), and an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/16/27910?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/6/31847?source=see_link\">",
"     magnesium hydroxide",
"    </a>",
"    mixture (Maalox&reg;) as a swish-and-spit as needed, up to four times per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Severe oral mucosal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive oral mucosal involvement may result in severe pain, leading to an inability to ingest foods or liquids. Systemic glucocorticoids are often used in an attempt to decrease the severity of symptoms and to shorten the course of the disease. However, no high-quality studies on the efficacy of this approach have been performed in EM.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (40 to 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    tapered over two to three weeks) was the only effective treatment in one series of 11 patients with recurrent oral EM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/4\">",
"     4",
"    </a>",
"    ]. However, some authors have expressed concern that glucocorticoids only partially suppress disease activity and may increase the risk for disease chronicity and prolonged duration of attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest short courses of oral glucocorticoids",
"    <strong>",
"     only",
"    </strong>",
"    in patients with severe and debilitating EM with mucosal involvement. The usual starting dose is 40 to 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent tapered over two to four weeks. Patients manifesting severe mucous membrane involvement that prevents sufficient oral intake may require hospitalization for nutrition and pain control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ocular involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ocular involvement should be referred immediately to an ophthalmologist for assessment and treatment to prevent long-term sequelae. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37672?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\", section on 'Course'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy usually involves the use of topical ophthalmic preparations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVENTION OF RECURRENT EM",
"    </span>",
"    &nbsp;&mdash;&nbsp;When feasible, as in drug-induced EM, the inciting cause of recurrent EM should be eliminated. However, this is not possible in most cases of recurrent EM (eg, HSV-associated EM or idiopathic EM). Patients who experience six or more recurrences per year or who have fewer, but debilitating episodes of EM are candidates for systemic prophylactic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37672?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\", section on 'Recurrent EM'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic antiviral medication is the first-line treatment for HSV-induced recurrent EM and recurrent EM without an identifiable cause. Immunosuppressive or immunomodulatory therapies are used for patients who do not improve with antiviral drugs.",
"   </p>",
"   <p>",
"    Two studies of patients with recurrent EM seen in tertiary care centers found average rates of recurrence of six episodes per year, with mean durations of disease ranging from 6 to 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. Thus, therapy to prevent recurrent disease may be necessary for a prolonged period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three approaches to antiviral prophylaxis have been evaluated in patients with recurrent EM: continuous antiviral therapy, which is the preferred approach, intermittent antiviral prophylaxis, and topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Continuous antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous antiviral therapy often is effective for the prevention of recurrent HSV-associated EM. The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (400 mg twice daily) was investigated in a six month, randomized trial of 20 patients, the majority of whom were known to have HSV-induced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients treated with acyclovir therapy were less likely to have recurrent attacks than patients given placebo (36 versus 100 percent), and the median number of attacks per patient was significantly lower (0 versus 3).",
"   </p>",
"   <p>",
"    Published case series have supported these results, reporting complete or partial responses to continuous antiviral therapy in over 90 percent of patients with known HSV-associated EM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. In one of these studies, remission of EM was maintained in only 4 of 15 patients following discontinuation of a six month course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, antiviral therapy is much less effective in EM that is not clearly associated with HSV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. The presence of subclinical HSV infection may account for patients who respond to antiviral therapy, but have no history of cutaneous signs of HSV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the tolerability of systemic antiviral drugs and the possibility of subclinical HSV infection as a cause for EM, we suggest a six month trial of antiviral suppressive therapy in all patients with idiopathic recurrent EM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18730881\">",
"    <span class=\"h4\">",
"     Choice of antiviral agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that the response to therapy may vary among antiviral drugs. The results of one series in which patients with both HSV-associated and idiopathic EM were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    suggested that valacyclovir may be more likely to induce complete responses than the other two drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, a case report described valacyclovir-induced remission of EM after failure of acyclovir therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The low cost of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    makes it the preferred drug for some patients, and the data above is not sufficient to determine superiority of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    over acyclovir and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    . We typically use any of these three agents for the initial treatment of recurrent EM. We suggest a six month trial of one of the following regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"       Acyclovir",
"      </a>",
"      &mdash; 400 mg twice daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/44/39622?source=see_link\">",
"       Valacyclovir",
"      </a>",
"      &mdash; 500 mg twice daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/23/37238?source=see_link\">",
"       Famciclovir",
"      </a>",
"      &mdash; 250 mg twice daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who fail initial treatment with an antiviral agent, the above doses can be doubled. If this is not effective, a trial of an alternative antiviral should be considered.",
"   </p>",
"   <p>",
"    There are not sufficient data to support specific recommendations for the duration of treatment in patients with recurrent EM who respond to continuous antiviral therapy. We typically treat for one to two years prior to attempting to discontinue therapy. If EM recurs after treatment is stopped, we restart the antiviral drug at the lowest effective dose and reattempt cessation of therapy every 6 to 12 months thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Intermittent antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A short course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy given at the initial sign of recurrent HSV infection decreased the incidence of recurrent EM in a series of 35 patients with EM that was clearly associated with HSV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/2\">",
"     2",
"    </a>",
"    ]. However, this regimen does not appear to be as effective as continuous antiviral therapy, which is the preferred approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Topical acyclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited on the efficacy of topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    . In a randomized cross-over trial of 18 patients, daily application of topical 5% acyclovir cream to areas of recurrent HSV infection was not effective for the prevention of HSV-associated recurrent EM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Second-line systemic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have recurrent EM despite a course of continuous antiviral therapy, other systemic agents should be considered.",
"   </p>",
"   <p>",
"    We suggest treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (100 to 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or 2",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    in patients with normal thiopurine methyltransferase activity),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (1000 mg twice daily), or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    (100 to 200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    although data on efficacy are limited.",
"   </p>",
"   <p>",
"    Based upon our experience, treatment should be continued for at least six months before concluding that a drug is ineffective. For patients who achieve remission, we continue therapy for 6 to 12 months followed by a taper of the medication (over two to four months) to the lowest effective dose or to cessation. If EM recurs, we restart the drug at the lowest effective dose for four to six months prior to another attempt at tapering.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    has been reported in case reports and small series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/2,5,10,11\">",
"     2,5,10,11",
"    </a>",
"    ]. In one report, azathioprine (100 to 150 mg daily) was associated with complete disease suppression in 11 patients with severe recurrent EM who failed all other therapies, although the condition recurred upon discontinuing therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/2\">",
"     2",
"    </a>",
"    ]. Azathioprine was less effective in another series, as only two out of five patients achieved complete or partial response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myelosuppression is a serious adverse effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    that may occur more frequently in patients with low activity of thiopurine methyltransferase (TPMT), an enzyme involved in the metabolism of this drug. We typically test for TPMT activity prior to initiating therapy with azathioprine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of pharmacogenomics\", section on 'Thiopurine methyltransferase'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil may have efficacy for the treatment of recurrent EM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. One series of 48 patients with recurrent EM found that six out of the eight patients treated with mycophenolate mofetil achieved complete or partial suppression of disease, a rate higher than was seen with other immunosuppressive agents, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/7\">",
"     7",
"    </a>",
"    ]. Given the small number of patients, further studies are necessary to determine whether mycophenolate mofetil should be used preferentially for the treatment of severe EM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    has been effective for recurrent EM in small series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. In a study of nine patients with recurrent EM treated with dapsone, eight had either partial or complete suppression of disease at a dose of 100 to 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/2\">",
"     2",
"    </a>",
"    ]. In another report of 10 patients, dapsone (&le;200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    led to complete suppression of disease in three patients and partial suppression in two patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hematologic side effects including hemolytic anemia (especially in glucose-6-phosphate deficient individuals), methemoglobinemia, and agranulocytosis may occur with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other treatments that have been utilized for the treatment of EM include intramuscular immunoglobulin G [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/2,13\">",
"     2,13",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/2\">",
"     2",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/14\">",
"     14",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], interferon alfa (in cases secondary to hepatitis C virus infection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Adverse prognostic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following features have been associated with a less favorable prognosis for disease control in patients with recurrent EM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41334/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inability to identify a specific cause",
"     </li>",
"     <li>",
"      Lack of improvement with continuous antiviral therapy",
"     </li>",
"     <li>",
"      Severe oral involvement",
"     </li>",
"     <li>",
"      Almost continuous use of glucocorticoid therapy for more than one year",
"     </li>",
"     <li>",
"      History of use of two or more immunosuppressive agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/3/21553?source=see_link\">",
"       \"Patient information: Erythema multiforme (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythema multiforme is an acute immune-mediated disorder that involves the skin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mucosal surfaces. The treatment of acute EM varies according to the severity of the acute eruption and the presence or absence of recurrent disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many cases of EM occur secondary to HSV infection. In patients with HSV-induced EM, treatment with oral antivirals in the acute setting does not alter the course of EM, and is not indicated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Inciting agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with EM can be managed with symptomatic therapy alone. For patients with cutaneous disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mild oral mucosal involvement, treatment with topical corticosteroids, oral antihistamines,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an anesthetic mouthwash is sufficient. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mild disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe oral mucosal involvement may be accompanied by intense pain and an inability to eat or drink. For patients with severe oral mucosal involvement, we suggest treatment with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (40 to 60",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      tapered over the course of two to four weeks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients with disabling symptoms may require hospitalization for nutrition and pain control. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Severe oral mucosal involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ocular involvement rarely may lead to keratitis, conjunctival scarring, or visual impairment. Patients with ocular symptoms should be referred to an ophthalmologist. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37672?source=see_link&amp;anchor=H9#H9\">",
"       \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\", section on 'Course'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H6\">",
"       'Ocular involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with EM develop recurrent disease. When feasible, the inciting agent should be identified and eliminated. For patients with HSV-induced or idiopathic EM that recurs &ge;6 times per year, or who have fewer, but disabling episodes, we recommend treatment with continuous antiviral therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Continuous antiviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe, recurrent EM who fail to respond to continuous systemic antiviral therapy, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other options for therapy include other immunomodulatory drugs. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Second-line systemic therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/1\">",
"      Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995; 131:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/2\">",
"      Schofield JK, Tatnall FM, Leigh IM. Recurrent erythema multiforme: clinical features and treatment in a large series of patients. Br J Dermatol 1993; 128:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/3\">",
"      Weston WL, Morelli JG. Herpes simplex virus-associated erythema multiforme in prepubertal children. Arch Pediatr Adolesc Med 1997; 151:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/4\">",
"      Bean SF, Quezada RK. Recurrent oral erythema multiforme. Clinical experience with 11 patients. JAMA 1983; 249:2810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/5\">",
"      Farthing PM, Maragou P, Coates M, et al. Characteristics of the oral lesions in patients with cutaneous recurrent erythema multiforme. J Oral Pathol Med 1995; 24:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/6\">",
"      Tatnall FM, Schofield JK, Leigh IM. A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme. Br J Dermatol 1995; 132:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/7\">",
"      Wetter DA, Davis MD. Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007. J Am Acad Dermatol 2010; 62:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/8\">",
"      Kerob D, Assier-Bonnet H, Esnault-Gelly P, et al. Recurrent erythema multiforme unresponsive to acyclovir prophylaxis and responsive to valacyclovir continuous therapy. Arch Dermatol 1998; 134:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/9\">",
"      Fawcett HA, Wansbrough-Jones MH, Clark AE, Leigh IM. Prophylactic topical acyclovir for frequent recurrent herpes simplex infection with and without erythema multiforme. Br Med J (Clin Res Ed) 1983; 287:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/10\">",
"      Sen P, Chua SH. A case of recurrent erythema multiforme and its therapeutic complications. Ann Acad Med Singapore 2004; 33:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/11\">",
"      Jones RR. Azathioprine therapy in the management of persistent erythema multiforme. Br J Dermatol 1981; 105:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/12\">",
"      Davis MD, Rogers RS 3rd, Pittelkow MR. Recurrent erythema multiforme/Stevens-Johnson syndrome: response to mycophenolate mofetil. Arch Dermatol 2002; 138:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/13\">",
"      Leigh IM, Mowbray JF, Levene GM, Sutherland S. Recurrent and continuous erythema multiforme--a clinical and immunological study. Clin Exp Dermatol 1985; 10:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/14\">",
"      Bakis S, Zagarella S. Intermittent oral cyclosporin for recurrent herpes simplex-associated erythema multiforme. Australas J Dermatol 2005; 46:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/15\">",
"      Moisson YF, Janier M, Civatte J. Thalidomide for recurrent erythema multiforme. Br J Dermatol 1992; 126:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/16\">",
"      Cherouati K, Claudy A, Souteyrand P, et al. [Treatment by thalidomide of chronic multiforme erythema: its recurrent and continuous variants. A retrospective study of 26 patients]. Ann Dermatol Venereol 1996; 123:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/17\">",
"      Dumas V, Thieulent N, Souillet AL, et al. Recurrent erythema multiforme and chronic hepatitis C: efficacy of interferon alpha. Br J Dermatol 2000; 142:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/18\">",
"      Geraminejad P, Walling HW, Voigt MD, Stone MS. Severe erythema multiforme responding to interferon alfa. J Am Acad Dermatol 2006; 54:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41334/abstract/19\">",
"      K&uuml;rk&ccedil;&uuml;olu N, Alli N. Cimetidine prevents recurrent erythema multiforme major resulting from herpes simplex virus infection. J Am Acad Dermatol 1989; 21:814.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5561 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_23_41334=[""].join("\n");
var outline_f40_23_41334=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT OF ACUTE EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Inciting agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mild disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Severe oral mucosal involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ocular involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVENTION OF RECURRENT EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Continuous antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18730881\">",
"      Choice of antiviral agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Intermittent antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Topical acyclovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Second-line systemic therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Dapsone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Adverse prognostic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5561\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5561|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/16/9478\" title=\"picture 1A\">",
"      Erythema multiforme target",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/53/19283\" title=\"picture 1B\">",
"      Erythema multiforme target2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/14/13540\" title=\"picture 1C\">",
"      Erythema multiforme acral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/36/25155\" title=\"picture 1D\">",
"      Erythema multiforme face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/4/9284\" title=\"picture 1E\">",
"      Erythema multiforme tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/51/14131\" title=\"picture 1F\">",
"      Erythema multiforme genital",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5561|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/50/37672?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/3/21553?source=related_link\">",
"      Patient information: Erythema multiforme (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_23_41335="Etiology and prognosis of neonatal seizures";
var content_f40_23_41335=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and prognosis of neonatal seizures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/23/41335/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/23/41335/contributors\">",
"     Eli M Mizrahi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/23/41335/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/23/41335/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/23/41335/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/23/41335/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/23/41335/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/23/41335/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying the etiology of seizures is a primary clinical objective in the management of neonatal seizures. Accurate determination of the cause can lead to etiology-specific therapy and may limit central nervous system (CNS) dysfunction that would otherwise occur if the underlying condition is left untreated. Etiology-specific therapy may also be necessary to control the seizures themselves.",
"   </p>",
"   <p>",
"    While there has been much discussion of the potential adverse effect of seizures on the immature brain, the most likely overriding factors that affect long-term outcome are the etiology of the seizures and the degree and distribution of brain injury caused by the underlying disturbance.",
"   </p>",
"   <p>",
"    This topic review will discuss neonatal seizures in terms of their etiologies and will focus on acute reactive seizures. The much less common neonatal epileptic syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35783?source=see_link\">",
"     \"Neonatal epileptic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characterization of various types of neonatal seizures, with an emphasis upon clinical features and electrodiagnosis, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/11/6328?source=see_link\">",
"     \"Clinical features and electrodiagnosis of neonatal seizures\"",
"    </a>",
"    .) Treatment is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/13?source=see_link\">",
"     \"Treatment of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all neonatal seizures may be categorized as \"symptomatic\" seizures, occurring as a consequence of a specific identifiable etiology (",
"    <a class=\"graphic graphic_table graphicRef73867 \" href=\"mobipreview.htm?7/34/7724\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/1\">",
"     1",
"    </a>",
"    ]. The seizures are considered acute and reactive, with prognosis varying according to specific etiology. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Acute reactive seizures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, despite a complete evaluation for etiology, there will be some seizures that occur in the absence of any identifiable cause. When associated with other clinical signs that suggest CNS injury, their etiology may be considered \"cryptogenic.\" When such seizures occur in otherwise normal infants, the seizures may be considered \"idiopathic.\"",
"   </p>",
"   <p>",
"    Although the majority of neonatal seizures occur as acute reactive events in response to identifiable etiologic factors, additional rare but distinct neonatal epileptic syndromes are well recognized. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Benign neonatal convulsions",
"     </li>",
"     <li>",
"      Benign neonatal familial convulsions",
"     </li>",
"     <li>",
"      Early myoclonic encephalopathy",
"     </li>",
"     <li>",
"      Early infantile epileptic encephalopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The International League Against Epilepsy (ILAE) has classified these epileptic syndromes with the purposes of standardizing terminology and developing a more uniform understanding of the clinical features and consequences of these disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. In the ILAE scheme, the syndromes are characterized by a cluster of clinical signs, symptoms, and laboratory findings that include seizure type, age of onset, etiology, precipitating factors, severity, ictal and interictal EEG findings, duration of the disorder, associated clinical features, chronicity, response to antiepileptic drug (AED) therapy, and prognosis. In the most recent 2005-2009 ILAE commission proposal, benign neonatal convulsions has been eliminated because of its diminished occurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizures associated with these ILAE designated syndromes are relatively rare. However, their identification can be important in the management of affected infants, as one has a benign prognosis and two have a poor prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35783?source=see_link\">",
"     \"Neonatal epileptic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACUTE REACTIVE SEIZURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic neonatal seizures may result from a wide range of possible etiologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], and Table 1 lists the major etiologies in order of their relative occurrence (",
"    <a class=\"graphic graphic_table graphicRef73867 \" href=\"mobipreview.htm?7/34/7724\">",
"     table 1",
"    </a>",
"    ). A more comprehensive list is provided in another Table (",
"    <a class=\"graphic graphic_table graphicRef76726 \" href=\"mobipreview.htm?7/10/7341\">",
"     table 2",
"    </a>",
"    ), with entities divided according to relative acuity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/8\">",
"     8",
"    </a>",
"    ]. Most etiologies can be broadly categorized as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neonatal encephalopathy and hypoxic-ischemic encephalopathy",
"     </li>",
"     <li>",
"      Metabolic disturbances",
"     </li>",
"     <li>",
"      CNS or systemic infections",
"     </li>",
"     <li>",
"      Structural brain lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initial evaluations are typically directed toward these etiologies, particularly the metabolic and infectious causes, since they are the most likely to be amenable to treatment.",
"   </p>",
"   <p>",
"    An orderly approach to the determination of the etiology of acute reactive neonatal seizures can be instituted in parallel with treatment (",
"    <a class=\"graphic graphic_table graphicRef71967 \" href=\"mobipreview.htm?5/4/5196\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/8\">",
"     8",
"    </a>",
"    ]. One of the main distinctions that is made early in seizure management is whether the seizures are epileptic or nonepileptic in origin. While such distinctions may have therapeutic and prognostic implications, they should not deter the clinician from a thorough evaluation of cause, since both types can be the result of significant CNS disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/13?source=see_link\">",
"     \"Treatment of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, whether seizures are considered to be epileptic or nonepileptic, the occurrence of any seizure indicates the presence of CNS dysfunction and warrants thorough evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neonatal encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal encephalopathy occurring as the result of hypoxia-ischemia is the most common cause of neonatal seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/9\">",
"     9",
"    </a>",
"    ]. The diagnosis of neonatal encephalopathy and hypoxic-ischemic encephalopathy (HIE) may, at times, be difficult to make because criteria vary among institutions, and because established criteria may be too restrictive or may not be predictive of the occurrence of long-term neurologic sequelae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. However, most currently applied criteria include considerations such as Apgar scores, need for resuscitation in the delivery room, recognition of clinical aspects of encephalopathy, altered state of alertness, acidosis, multisystem organ dysfunction, and seizures.",
"   </p>",
"   <p>",
"    The combined presence of an Apgar score &lt;5 at five minutes, pH &lt;7.0, and intubation in the delivery room were found to have a positive predictive value of 80 percent for clinical seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/14\">",
"     14",
"    </a>",
"    ]. However, many neonatal seizures are not recognized clinically. In an EEG monitoring study, only the 5-minute Apgar was found to be associated with the risk of electroencephalographic seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/15\">",
"     15",
"    </a>",
"    ]. Seizures in this setting usually occur within the first one to two days of birth and often remit after a few days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neonatal encephalopathy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30953?source=see_link\">",
"     \"Etiology and pathogenesis of neonatal encephalopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2442?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Metabolic disturbances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potentially treatable metabolic etiologies include hypocalcemia, hypomagnesemia, and hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35188?source=see_link\">",
"     \"Metabolic emergencies at birth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/26999?source=see_link\">",
"     \"Neonatal hypocalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potentially treatable causes of medically refractory neonatal seizures have been reported to include pyridoxine deficiency (which is exceedingly rare) and biotinidase deficiency (also a rare disorder). This has led to a sequence of empirical therapies in infants with medically refractory neonatal seizures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/13?source=see_link\">",
"     \"Treatment of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, neonatal seizures are associated with the in-born errors of metabolism, such as aminoacidurias, urea cycle defects, or organic acidurias. While the typical presentation usually includes poor feeding, lethargy, and respiratory distress after an initial symptom-free period of a few to several days, some infants present with isolated seizures. These disorders should be suspected when seizures begin prepartum (although this is a rare and difficult-to-determine finding), are refractory to conventional treatment, are associated with progressive clinical and electroencephalographic worsening, and there are imaging findings of prominent brain atrophy or hypoxic-ischemic injury without a history of insult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The associated clinical features typical of inborn errors of metabolism are discussed separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     CNS infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial and viral infections of the CNS are important causes of seizures as well as their adverse sequelae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, prenatal infections are potential risk factors for seizures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24246?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in the neonate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31656?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28041?source=see_link&amp;anchor=H650131395#H650131395\">",
"     \"Overview of TORCH infections\", section on 'Clinical features of TORCH infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Structural brain lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structural brain lesions associated with neonatal seizures include hemorrhage (intracerebral, subarachnoid, intraventricular), infarctions, and congenital anomalies of the brain. Hemorrhage and infarction may occur in isolation or may be the consequence of other etiologies such as CNS infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/46/31465?source=see_link\">",
"     \"Management and complications of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27690?source=see_link\">",
"     \"Stroke in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neonatal seizures may also occur after infant heart surgery. In one series of 183 infants monitored with video EEG for 48 hours postoperatively, electrographic neonatal seizures (none clinically visible) were noted in 21 (11 percent) infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/19\">",
"     19",
"    </a>",
"    ]. Brain abnormalities, including diffuse periventricular leukomalacia or global hypoxic-ischemic injury, were found in 15 of 16 who had MRI. In contrast, another study utilizing specific anesthetic and surgical protocols reported a much lower seizure occurrence, 1 of 68 infants following cardiac surgery and cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Congenital anomalies of the brain have become more widely recognized as associated findings of neonatal seizures with increased resolution and application of MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111412038\">",
"    <span class=\"h2\">",
"     Drug withdrawal or intoxication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates exposed to chronic opioids, alcohol, benzodiazepines,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    barbiturates in utero may suffer a withdrawal syndrome in the first days of life that can include seizures.",
"   </p>",
"   <p>",
"    The clinical features and management of these syndromes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28746?source=see_link\">",
"     \"Infants of mothers with substance abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/57/39833?source=see_link\">",
"     \"Neonatal opioid withdrawal (Neonatal abstinence syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NEONATAL EPILEPTIC SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the three neonatal seizure syndromes recognized by the ILAE is considered benign, as its name implies, and is associated with a relatively good prognosis: benign familial neonatal convulsions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. In contrast, early (neonatal) myoclonic encephalopathy (EME) and early infantile epileptic encephalopathy (EIEE) are often categorized as severe neonatal epilepsy syndromes because of their poor prognosis (",
"    <a class=\"graphic graphic_table graphicRef76108 \" href=\"mobipreview.htm?22/10/22700\">",
"     table 4",
"    </a>",
"    ). These syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35783?source=see_link\">",
"     \"Neonatal epileptic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of acute reactive neonatal seizures is directed toward correcting the underlying etiology when this is possible (",
"    <a class=\"graphic graphic_table graphicRef73867 \" href=\"mobipreview.htm?7/34/7724\">",
"     table 1",
"    </a>",
"    ). Antiepileptic drugs (AEDs), particularly",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    , and benzodiazepines, are used in select cases. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/13?source=see_link\">",
"     \"Treatment of neonatal seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consequences of acute reactive seizures in neonates are determined mainly by the etiology of the seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Seizure duration and use of AEDs may also have some impact, but this has yet to be fully defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/28\">",
"     28",
"    </a>",
"    ]. The same is true of neonates who have a clearly defined epileptic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35783?source=see_link\">",
"     \"Neonatal epileptic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mortality and neurologic impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a high incidence of early death (24 to 30 percent) associated with neonatal seizures, and a high incidence of neurologic impairment, developmental delay, and postneonatal epilepsy among survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/27,29-34\">",
"     27,29-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For infants with neonatal seizures who were followed until 17 months to 10 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/29-33\">",
"     29-33",
"    </a>",
"    ], the following ranges of outcomes have been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormalities on neurologic examination in 42 to 59 percent",
"     </li>",
"     <li>",
"      Developmental delay in 55 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mental retardation in 20 to 40 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cerebral palsy in 25 to 43 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Learning disabilities in 27 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      No neurologic abnormalities in 22 to 35 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Postneonatal epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postneonatal epilepsy has been reported to occur in between 20 to 30 percent of survivors of neonatal seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/29-33,35-37\">",
"     29-33,35-37",
"    </a>",
"    ], and rates as high as 56 percent have been reported among populations with relatively high risk factors for CNS dysfunction, such as more frequent seizures or status epilepticus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. When seizures do occur in the postneonatal period, they most often do so within the first six to nine months of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/32,35\">",
"     32,35",
"    </a>",
"    ]; seizures may be either partial or generalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mechanisms of brain injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to assess the relative contribution of various factors that may determine long-term outcome of those who have experienced neonatal seizures: the direct effect of seizures on the developing brain, the indirect effect of seizures, direct or indirect effects of AEDs, or the effect of the underlying cause of seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/41\">",
"     41",
"    </a>",
"    ]. Immature animals are more resistant to some types of seizure-induced brain injury than are older animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/42\">",
"     42",
"    </a>",
"    ]. However, there eventually may be functional abnormalities in older animals that have had seizures during the neonatal period. These include impairment of visual-spatial memory and reduced seizure threshold that, in part, are related to altered synaptogenesis and reduction in neurogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In clinical practice it may appear that seizure duration influences outcome, since infants who experience brief and infrequent seizures can have relatively good long-term outcomes, while those with prolonged seizures may not do as well. However, easily controlled seizures or self-limited seizures are often the result of transient etiologic-specific treated or benign CNS disorders of neonates, while medically refractory neonatal seizures may be the result of more sustained, less treatable, or more severe brain disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study found that a greater amount of electrographic seizure activity correlated with subsequent relative increased mortality and morbidity in at-risk infants in general, and also in infants with perinatal asphyxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, other investigators utilizing proton magnetic resonance spectroscopy (H-MRS) in neonates found both an association of seizure severity with impaired cerebral metabolism measured by",
"    <span class=\"nowrap\">",
"     lactate/choline,",
"    </span>",
"    and compromised neuronal integrity measured by",
"    <span class=\"nowrap\">",
"     N-acetylaspartate/choline",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/47\">",
"     47",
"    </a>",
"    ]. These results suggest that brain injury is not limited to structural damage detected by MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Predictive variables",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dominant factor that predicts outcome appears to be the underlying cause of the seizures rather than the presence, duration, or degree of brain involvement of the epileptic seizures themselves. In clinical studies, normal developmental outcomes are less frequent in association with HIE, severe infection, or hemorrhage, compared with those associated with hypoglycemia and hypocalcemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/6,27,48-55\">",
"     6,27,48-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizure type may also predict outcome, due in part to the degree of CNS dysfunction typically associated with various categories of seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/31,32,56\">",
"     31,32,56",
"    </a>",
"    ]. The presence of focal-clonic and focal-tonic seizures suggests a relatively good outcome primarily because these are typically associated with brain injury confined to one region and spared CNS function in the remaining brain regions. Generalized tonic posturing, motor automatisms, and myoclonus suggest a poor outcome, since they are associated with diffuse CNS dysfunction.",
"   </p>",
"   <p>",
"    A number of clinical variables in addition to etiology and character of the seizures may be predictors of outcome; these include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/26,27,32,55-59\">",
"     26,27,32,55-59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      features of the interictal EEG from one or serial recordings",
"     </li>",
"     <li>",
"      features of the ictal EEG",
"     </li>",
"     <li>",
"      seizure burden, including the number of sites of seizure onset and seizure duration",
"     </li>",
"     <li>",
"      status epilepticus",
"     </li>",
"     <li>",
"      the neurologic examination at the time of seizures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41335/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      number of drugs required to treat seizures",
"     </li>",
"     <li>",
"      findings on neuroimaging",
"     </li>",
"     <li>",
"      conceptional age (term versus preterm)",
"     </li>",
"     <li>",
"      birth weight",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple rather than single factors appear to be most accurate in predicting outcome. However, all these variables ultimately are related to the degree of brain injury at the time of seizure occurrence, and, in turn, the seizure etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111412071\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Almost all neonatal seizures may be categorized as \"symptomatic\" (acute and reactive) seizures, occurring as a consequence of a specific identifiable etiology (",
"      <a class=\"graphic graphic_table graphicRef73867 \" href=\"mobipreview.htm?7/34/7724\">",
"       table 1",
"      </a>",
"      ). Neonatal encephalopathy occurring as the result of hypoxia-ischemia is the most common of these etiologies. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute reactive seizures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some neonatal seizures occur in the absence of any identifiable cause. When associated with other clinical signs that suggest CNS injury, their etiology may be considered \"cryptogenic.\" When such seizures occur in otherwise normal infants, the seizures may be considered \"idiopathic.\" (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Four rare but distinct neonatal epileptic syndromes are well recognized: benign neonatal convulsions, benign neonatal familial convulsions, early myoclonic encephalopathy, and early infantile epileptic encephalopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35783?source=see_link\">",
"       \"Neonatal epileptic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is a high incidence of early death (24 to 30 percent) associated with neonatal seizures, as well as a high incidence of neurologic impairments (20 to 60 percent), developmental delay (up to 55 percent), and postneonatal epilepsy (20 to 30 percent) among survivors. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most likely overriding factors that affect long-term outcome are the etiology of the seizures and the degree and distribution of brain injury caused by the underlying disturbance. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Predictive variables'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Mizrahi EM, Watanabe K. Symptomatic neonatal seizures. In: Epileptic syndromes in infancy, childhood and adolescence, 3rd, Roger J, Bureau M, Dravet CH, et al.  (Eds), John Libbey, 2002. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/2\">",
"      Proposal for classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1985; 26:268.",
"     </a>",
"    </li>",
"    <li>",
"     Wolfe P. International classification of the epilepsies. In: Epilepsy: A Comprehensive Textbook, Engel J Jr, Pedley TA.  (Eds), Lippincott-Raven, Philadelphia 1997. p.773.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/4\">",
"      Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989; 30:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/5\">",
"      Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010; 51:676.",
"     </a>",
"    </li>",
"    <li>",
"     Mizrahi EM, Kellaway P. Diagnosis and Management of Neonatal Seizures, Lippincott-Raven, Philadelphia 1998. p.181.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/7\">",
"      Co JP, Elia M, Engel J Jr, et al. Proposal of an algorithm for diagnosis and treatment of neonatal seizures in developing countries. Epilepsia 2007; 48:1158.",
"     </a>",
"    </li>",
"    <li>",
"     Chapman KE, Mizrahi EM, Clancy, RR. Neonatal seizures. In: Wyllie's Treatment of Epilepsy: Principles and Practice, 5th, Lippincott, Williams &amp; Wilkens, Philadelphia.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/9\">",
"      Lynch NE, Stevenson NJ, Livingstone V, et al. The temporal evolution of electrographic seizure burden in neonatal hypoxic ischemic encephalopathy. Epilepsia 2012; 53:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/10\">",
"      Nelson KB, Leviton A. How much of neonatal encephalopathy is due to birth asphyxia? Am J Dis Child 1991; 145:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/11\">",
"      Paneth N. The causes of cerebral palsy. Recent evidence. Clin Invest Med 1993; 16:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/12\">",
"      Leviton A, Nelson KB. Problems with definitions and classifications of newborn encephalopathy. Pediatr Neurol 1992; 8:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/13\">",
"      Perlman JM. Intrapartum hypoxic-ischemic cerebral injury and subsequent cerebral palsy: medicolegal issues. Pediatrics 1997; 99:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/14\">",
"      Perlman JM, Risser R. Can asphyxiated infants at risk for neonatal seizures be rapidly identified by current high-risk markers? Pediatrics 1996; 97:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/15\">",
"      Murray DM, Ryan CA, Boylan GB, et al. Prediction of seizures in asphyxiated neonates: correlation with continuous video-electroencephalographic monitoring. Pediatrics 2006; 118:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/16\">",
"      Ficicioglu C, Bearden D. Isolated neonatal seizures: when to suspect inborn errors of metabolism. Pediatr Neurol 2011; 45:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/17\">",
"      Dhamija R, Patterson MC, Wirrell EC. Epilepsy in children--when should we think neurometabolic disease? J Child Neurol 2012; 27:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/18\">",
"      Verboon-Maciolek MA, Groenendaal F, Hahn CD, et al. Human parechovirus causes encephalitis with white matter injury in neonates. Ann Neurol 2008; 64:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/19\">",
"      Clancy RR, Sharif U, Ichord R, et al. Electrographic neonatal seizures after infant heart surgery. Epilepsia 2005; 46:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/20\">",
"      Andropoulos DB, Mizrahi EM, Hrachovy RA, et al. Electroencephalographic seizures after neonatal cardiac surgery with high-flow cardiopulmonary bypass. Anesth Analg 2010; 110:1680.",
"     </a>",
"    </li>",
"    <li>",
"     Ohtahara S, Ohstsuka Y, Yamatogi Y, et al.. Early-infantile epileptic encephalopathy with supression-bursts. In: Epileptic Syndromes in Infancy, Childhood and Adolescence, 4th, Roger J, Bureau M, Dravet CH, et al.  (Eds), John Libbey &amp; Company, 2005. p.25.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/22\">",
"      Ohtahara S, Yamatogi Y. Epileptic encephalopathies in early infancy with suppression-burst. J Clin Neurophysiol 2003; 20:398.",
"     </a>",
"    </li>",
"    <li>",
"     Plouin P, Anderson VE. Benign familial and non-familial neonatal seizures. In: Epileptic Syndromes in Infancy, Childhood and Adolescence, Roger J, Bureau M, Dravet CH, et al.  (Eds), John Libbey &amp; Company, 2005. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/24\">",
"      Quattlebaum TG. Benign familial convulsions in the neonatal period and early infancy. J Pediatr 1979; 95:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/25\">",
"      Ronen GM, Rosales TO, Connolly M, et al. Seizure characteristics in chromosome 20 benign familial neonatal convulsions. Neurology 1993; 43:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/26\">",
"      Mizrahi EM, Clancy RR. Neonatal seizures: early-onset seizure syndromes and their consequences for development. Ment Retard Dev Disabil Res Rev 2000; 6:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/27\">",
"      Tekgul H, Gauvreau K, Soul J, et al. The current etiologic profile and neurodevelopmental outcome of seizures in term newborn infants. Pediatrics 2006; 117:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/28\">",
"      Maartens IA, Wassenberg T, Buijs J, et al. Neurodevelopmental outcome in full-term newborns with refractory neonatal seizures. Acta Paediatr 2012; 101:e173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/29\">",
"      Ortibus EL, Sum JM, Hahn JS. Predictive value of EEG for outcome and epilepsy following neonatal seizures. Electroencephalogr Clin Neurophysiol 1996; 98:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/30\">",
"      Blume WT, L&uuml;ders HO, Mizrahi E, et al. Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. Epilepsia 2001; 42:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/31\">",
"      Brunquell PJ, Glennon CM, DiMario FJ Jr, et al. Prediction of outcome based on clinical seizure type in newborn infants. J Pediatr 2002; 140:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/32\">",
"      Ronen GM, Buckley D, Penney S, Streiner DL. Long-term prognosis in children with neonatal seizures: a population-based study. Neurology 2007; 69:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/33\">",
"      Mizrahi EM, Clancy RR, Dunn JK, et al. Neurological impairment, developmental delay and postnatal seizures 2 years after EEG-video documented seizures in near-term and term neonates: a report of the clinical research centers for neonatal seizures. Epilepsia 2001; 42(Supplement 7):102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/34\">",
"      Davis AS, Hintz SR, Van Meurs KP, et al. Seizures in extremely low birth weight infants are associated with adverse outcome. J Pediatr 2010; 157:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/35\">",
"      Ellenberg JH, Hirtz DG, Nelson KB. Age at onset of seizures in young children. Ann Neurol 1984; 15:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/36\">",
"      Bye AM, Cunningham CA, Chee KY, Flanagan D. Outcome of neonates with electrographically identified seizures, or at risk of seizures. Pediatr Neurol 1997; 16:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/37\">",
"      Scher MS, Aso K, Beggarly ME, et al. Electrographic seizures in preterm and full-term neonates: clinical correlates, associated brain lesions, and risk for neurologic sequelae. Pediatrics 1993; 91:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/38\">",
"      Clancy RR, Legido A. Postnatal epilepsy after EEG-confirmed neonatal seizures. Epilepsia 1991; 32:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/39\">",
"      Pisani F, Cerminara C, Fusco C, Sisti L. Neonatal status epilepticus vs recurrent neonatal seizures: clinical findings and outcome. Neurology 2007; 69:2177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/40\">",
"      Watanabe K, Miura K, Natsume J, et al. Epilepsies of neonatal onset: seizure type and evolution. Dev Med Child Neurol 1999; 41:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/41\">",
"      Thibeault-Eybalin MP, Lortie A, Carmant L. Neonatal seizures: do they damage the brain? Pediatr Neurol 2009; 40:175.",
"     </a>",
"    </li>",
"    <li>",
"     Swann JW. Synaptogenesis and eliptogenesis in developing neural networks. In: Brain Development and Epilepsy, Schwartzkroin PA, Moshe SL, Noebels JL, Swann JW.  (Eds), Oxford University, New York 1995. p.195.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/43\">",
"      Holmes GL, Ben-Ari Y. The neurobiology and consequences of epilepsy in the developing brain. Pediatr Res 2001; 49:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/44\">",
"      Holmes GL, Khazipov R, Ben-Ari Y. Seizure-induced damage in the developing human: relevance of experimental models. Prog Brain Res 2002; 135:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/45\">",
"      Glass HC, Wirrell E. Controversies in neonatal seizure management. J Child Neurol 2009; 24:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/46\">",
"      McBride MC, Laroia N, Guillet R. Electrographic seizures in neonates correlate with poor neurodevelopmental outcome. Neurology 2000; 55:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/47\">",
"      Miller SP, Weiss J, Barnwell A, et al. Seizure-associated brain injury in term newborns with perinatal asphyxia. Neurology 2002; 58:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/48\">",
"      McInerny TK, Schubert WK. Prognosis of neonatal seizures. Am J Dis Child 1969; 117:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/49\">",
"      Rose AL, Lombroso CT. A study of clinical, pathological, and electroencephalographic features in 137 full-term babies with a long-term follow-up. Pediatrics 1970; 45:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/50\">",
"      Bergman I, Painter MJ, Hirsch RP, et al. Outcome in neonates with convulsions treated in an intensive care unit. Ann Neurol 1983; 14:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/51\">",
"      Lombroso CT. Prognosis in neonatal seizures. Adv Neurol 1983; 34:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/52\">",
"      Mannino FL, Trauner DA. Stroke in neonates. J Pediatr 1983; 102:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/53\">",
"      Clancy R, Malin S, Laraque D, et al. Focal motor seizures heralding stroke in full-term neonates. Am J Dis Child 1985; 139:601.",
"     </a>",
"    </li>",
"    <li>",
"     Kellaway P, Mizrahi EM. Neonatal seizures. In: Epilepsy: Electroclinical Syndromes, Luders H, Lesser RP.  (Eds), Springer-Verlag, New York 1987. p.13.",
"    </li>",
"    <li>",
"     Volpe JJ. Neurology of the Newborn. In: Neonatal Seizures, WB Sanders, Philadelphia 1995. p.172.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/56\">",
"      Mizrahi EM, Kellaway P. Characterization and classification of neonatal seizures. Neurology 1987; 37:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/57\">",
"      Pisani F, Copioli C, Di Gioia C, et al. Neonatal seizures: relation of ictal video-electroencephalography (EEG) findings with neurodevelopmental outcome. J Child Neurol 2008; 23:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/58\">",
"      Holmes GL, Lombroso CT. Prognostic value of background patterns in the neonatal EEG. J Clin Neurophysiol 1993; 10:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41335/abstract/59\">",
"      Laroia N, Guillet R, Burchfiel J, McBride MC. EEG background as predictor of electrographic seizures in high-risk neonates. Epilepsia 1998; 39:545.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6179 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_23_41335=[""].join("\n");
var outline_f40_23_41335=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H111412071\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACUTE REACTIVE SEIZURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Metabolic disturbances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CNS infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Structural brain lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111412038\">",
"      Drug withdrawal or intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NEONATAL EPILEPTIC SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mortality and neurologic impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Postneonatal epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mechanisms of brain injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Predictive variables",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111412071\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6179\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6179|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/34/7724\" title=\"table 1\">",
"      Etiologies of neonatal seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/10/7341\" title=\"table 2\">",
"      Causes of neonatal seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/4/5196\" title=\"table 3\">",
"      Testing for neonatal seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/10/22700\" title=\"table 4\">",
"      Comparison between EME and EIEE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/11/6328?source=related_link\">",
"      Clinical features and electrodiagnosis of neonatal seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/44/42697?source=related_link\">",
"      Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30953?source=related_link\">",
"      Etiology and pathogenesis of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28746?source=related_link\">",
"      Infants of mothers with substance abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/46/31465?source=related_link\">",
"      Management and complications of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35188?source=related_link\">",
"      Metabolic emergencies at birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35783?source=related_link\">",
"      Neonatal epileptic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/26999?source=related_link\">",
"      Neonatal hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/57/39833?source=related_link\">",
"      Neonatal opioid withdrawal (Neonatal abstinence syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31656?source=related_link\">",
"      Neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24246?source=related_link\">",
"      Neurologic complications of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28041?source=related_link\">",
"      Overview of TORCH infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27690?source=related_link\">",
"      Stroke in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/13?source=related_link\">",
"      Treatment of neonatal seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_23_41336="Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information";
var content_f40_23_41336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"    see \"Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/2/23589?source=see_link\">",
"    see \"Trimethoprim-sulfamethoxazole (co-trimoxazole): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bactrim&trade;;",
"     </li>",
"     <li>",
"      Bactrim&trade; DS;",
"     </li>",
"     <li>",
"      Septra&reg; DS",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sulfatrim&reg;;",
"     </li>",
"     <li>",
"      Apo-Sulfatrim&reg; DS;",
"     </li>",
"     <li>",
"      Apo-Sulfatrim&reg; Pediatric;",
"     </li>",
"     <li>",
"      Novo-Trimel;",
"     </li>",
"     <li>",
"      Novo-Trimel D.S.;",
"     </li>",
"     <li>",
"      Nu-Cotrimox;",
"     </li>",
"     <li>",
"      Septra&reg; Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Sulfonamide Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"      see \"Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage recommendations are based on the trimethoprim (TMP) component:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants 4 weeks to &lt;2 months (HIV-exposed/-positive; CDC, 2009):",
"     <b>",
"      <i>",
"       Pneumocystis",
"      </i>",
"      prophylaxis:",
"     </b>",
"     Oral: 150 mg TMP/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /day for 3-7 days of every week; total daily dose may be given in divided doses every 12 hours for 3 consecutive or alternating days, in divided doses every 12 hours every day or as a single daily dose for 3 consecutive days (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants &ge;2 months and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Mild to moderate infections:",
"     </b>",
"     Oral: 8-12 mg TMP/kg/day in divided doses every 12 hours (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Serious infection:",
"     </b>",
"     I.V.: 8-12 mg TMP/kg/day in divided doses every 6 hours (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acute otitis media:",
"     </b>",
"     Oral: 6-10 mg TMP/kg/day in divided doses every 12 hours for 10 days.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended by the American Academy of Pediatrics as an alternative agent in penicillin-allergic patients (AAP, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Cyclosporiasis",
"      </i>",
"      :",
"     </b>",
"     Oral, I.V.: 10 mg TMP/kg/day in divided doses twice daily for 7-10 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      MRSA, community-acquired mild to moderate skin/soft tissue infection:",
"     </b>",
"     Oral: 8-12 mg TMP/kg/day in divided doses every 12 hours (IDSA Guidelines; Liu, 2011); alternatively, use of 20 mg/kg/day in divided doses every 6 hours has been reported (Norrby-Teglund, 2008). If using empirically, consider addition of group A streptococcal coverage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Pneumocystis",
"      </i>",
"      :",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment: Oral, I.V.: 15-20 mg TMP/kg/day in divided doses every 6-8 hours for 21 days (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Prophylaxis: Oral: 150 mg TMP/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /day for 3-7 days of every week; total daily dose may be given in divided doses every 12 hours for 3 consecutive or alternating days, in divided doses every 12 hours every day or as a single daily dose for 3 consecutive days (maximum dose: Trimethoprim 320 mg and sulfamethoxazole 1600 mg daily) (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Shigellosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: 8 mg TMP/kg/day in divided doses every 12 hours for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 8-10 mg TMP/kg/day in divided doses every 6, 8, or 12 hours for up to 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Toxoplasmosis primary prophylaxis (HIV-exposed/infected):",
"     </b>",
"     Oral: 150 mg TMP/",
"     <b>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"     </b>",
"     /day in divided doses twice daily (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Urinary tract infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Oral: 6-12 mg TMP/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.V.: 8-10 mg TMP/kg/day in divided doses every 6, 8, or 12 hours for up to 14 days with serious infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Prophylaxis: Oral: 2 mg TMP/kg/dose daily or 5 mg TMP/kg/dose twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing guidelines:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: One double strength tablet (sulfamethoxazole 800 mg; trimethoprim 160 mg) every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 8-20 mg TMP/kg/day divided every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Chronic bronchitis (acute):",
"     </b>",
"     Oral: One double strength tablet every 12 hours for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Meningitis (bacterial):",
"     </b>",
"     I.V.: 10-20 mg TMP/kg/day in divided doses every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Nocardia",
"      </i>",
"      :",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cutaneous infections: 5-10 mg TMP/kg/day in 2-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Severe infections (pulmonary/cerebral): 15 mg TMP/kg/day in 2-4 divided doses for 3-4 weeks, then 10 mg TMP/kg/day in 2-4 divided doses. Treatment duration is controversial; an average of 7 months has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Therapy for severe infection may be initiated I.V. and converted to oral therapy (frequently converted to approximate dosages of oral solid dosage forms: 2 DS tablets every 8-12 hours). Although not widely available, sulfonamide levels should be considered in patients with questionable absorption, at risk for dose-related toxicity or those with poor therapeutic response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Pneumocystis jirovecii",
"      </i>",
"      :",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Prophylaxis: Oral: One double strength tablet daily or 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment: Oral, I.V.: 15-20 mg TMP/kg/day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Sepsis:",
"     </b>",
"     I.V.: 20 TMP/kg/day divided every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Shigellosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: One double strength tablet every 12 hours for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 8-10 mg TMP/kg/day in divided doses every 6, 8, or 12 hours for up to 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Skin/soft tissue infection due to community-acquired MRSA:",
"     </b>",
"     Oral: 1-2 double strength tablets every 12 hours (Liu, 2011; Stevens, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Travelers' diarrhea:",
"     </b>",
"     Oral: One double strength tablet every 12 hours for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Urinary tract infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Oral: One double strength tablet every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Duration of therapy: Uncomplicated: 3-5 days; Complicated: 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Pyelonephritis: 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Prostatitis: Acute: 2 weeks; Chronic: 2-3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 8-10 mg TMP/kg/day in divided doses every 6, 8, or 12 hours for up to 14 days with severe infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Manufacturer&rsquo;s recommendation: Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-30 mL/minute: Administer 50% of recommended dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute: Use is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alternate recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-30 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Treatment: Administer full daily dose (divided every 12 hours) for 24-48 hours, then decrease daily dose by 50% and administer every 24 hours (",
"     <b>",
"      Note:",
"     </b>",
"     For serious infections, including",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP), full daily dose is given in divided doses every 6-8 hours for 2 days, followed by reduction to 50% daily dose divided every 12 hours) (Nahata, 1995).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     PCP prophylaxis: One-half single-strength tablet (40 mg trimethoprim) daily",
"     <b>",
"      or",
"     </b>",
"     one single-strength tablet (80 mg trimethoprim) daily or 3 times weekly (Masur, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Treatment: Administer full daily dose every 48 hours (Nahata, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     PCP prophylaxis: One-half single-strength tablet (40 mg trimethoprim) daily",
"     <b>",
"      or",
"     </b>",
"     one single-strength tablet (80 mg trimethoprim) 3 times weekly (Masur, 2002). While the guidelines do acknowledge the alternative of giving one single-strength tablet daily, this may be inadvisable in the uremic/ESRD patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hemodialysis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Treatment: Full daily dose before dialysis and 50% dose after dialysis (Nahata, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children: GFR &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Not recommended, but if required 5-10 mg TMP/kg every 24 hours (Arnoff, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     PCP prophylaxis: One single-strength tablet (80 mg trimethoprim) after each dialysis session (Masur, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     CAPD: Use Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute dosing recommendations. Not significantly removed by CAPD; supplemental dosing is not required (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Exit-site and tunnel infections: Oral: One single-strength tablet daily (Li, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Peritonitis: Oral: One double-strength tablet twice daily (Li, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children: GFR &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Not recommended, but if required 5-10 mg TMP/kg every 24 hours. Intraperitoneal: Loading dose: TMP-SMX 320/1600 mg/L; Maintenance: TMP-SMX 80/400 mg/L (Arnoff, 2007; Warady, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     CRRT: 2.5-10 mg TMP/kg/dose every 12 hours (Heintz, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"     <b>",
"      Note:",
"     </b>",
"     The 5:1 ratio (SMX:TMP) remains constant in all dosage forms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: Sulfamethoxazole 80 mg and trimethoprim 16 mg per mL (5 mL, 10 mL, 30 mL) [contains benzyl alcohol, ethanol 12.2%, propylene glycol 400 mg/mL, sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: Sulfamethoxazole 200 mg and trimethoprim 40 mg per 5 mL (480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Tablet: Sulfamethoxazole 400 mg and trimethoprim 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bactrim&trade;: Sulfamethoxazole 400 mg and trimethoprim 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, double-strength: Sulfamethoxazole 800 mg and trimethoprim 160 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bactrim&trade; DS: Sulfamethoxazole 800 mg and trimethoprim 160 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Septra&reg; DS: Sulfamethoxazole 800 mg and trimethoprim 160 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May administer with water on an empty stomach; shake suspension well before use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"     <b>",
"      Do not administer I.M.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. infusion: Further dilute prior to administration [ie, diluted 1:25 (5 mL drug to 125 mL diluent, ie, D",
"     <sub>",
"      5",
"     </sub>",
"     W); in patients who require fluid restriction, a 1:15 dilution (5 mL drug to 75 mL diluent, ie, D",
"     <sub>",
"      5",
"     </sub>",
"     W) or a 1:10 dilution (5 mL drug to 50 mL diluent, ie, D",
"     <sub>",
"      5",
"     </sub>",
"     W)]. Inspect solution for evidence of cloudiness or precipitation prior to administration; infuse over 60-90 minutes; pH: 10",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F154913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W,  D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, aldesleukin, allopurinol, amifostine, Aminosyn&reg; II, amphotericin B cholesteryl sulfate complex, anidulafungin, atracurium, aztreonam, bivalirudin, cefepime, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, docetaxel, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, fenoldopam, filgrastim, fludarabine, gallium nitrate, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, labetalol, linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, morphine, nicardipine, oxytocin, pancuronium, pemetrexed, piperacillin/tazobactam, remifentanil, sargramostim, tacrolimus, teniposide, thiotepa, vecuronium, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caspofungin, fluconazole, midazolam, pantoprazole, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cisatracurium, foscarnet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydramine, heparin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Store at room temperature, 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not refrigerate. Protect from light. Less soluble in alkaline pH. Solution must be diluted prior to administration; do not mix with other drugs or solutions. Following dilution, store at room temperature; do not refrigerate. Manufacturer recommended dilutions and stability of parenteral admixture at room temperature (25&deg;C):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     5 mL/125 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W (1:25 dilution); stable for 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     5 mL/100 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W (1:20 dilution); stable for 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     5 mL/75 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W (1:15 dilution); stable for 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     5 mL/50 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W (1:10 highly concentrated admixture) may precipitate in 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Studies have also confirmed limited stability in NS; detailed references should be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Suspension, tablet: Store at controlled room temperature of 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Treatment of urinary tract infections caused by susceptible",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella",
"     </i>",
"     and",
"     <i>",
"      Enterobacter",
"     </i>",
"     sp.,",
"     <i>",
"      M. morganii",
"     </i>",
"     ,",
"     <i>",
"      P. mirabilis",
"     </i>",
"     and",
"     <i>",
"      P. vulgaris",
"     </i>",
"     (FDA approved in ages &ge;2 months and adults); single course treatment of acute otitis media due to",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     , and",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     (FDA approved in ages &ge;2 months and adults); prophylaxis and treatment of",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonitis (PCP) [FDA approved in pediatric patients (age not specified) and adults]; treatment of enteritis caused by",
"     <i>",
"      Shigella flexneri",
"     </i>",
"     or",
"     <i>",
"      Shigella sonnei",
"     </i>",
"     (FDA approved in ages &ge;2 months and adults); acute exacerbations of chronic bronchitis due to susceptible strains of",
"     <i>",
"      H. influenzae",
"     </i>",
"     or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (FDA approved in adults); traveler's diarrhea due to enterotoxigenic",
"     <i>",
"      E. coli",
"     </i>",
"     (FDA approved in adults). Has also been used in typhoid fever,",
"     <i>",
"      Nocardia asteroids",
"     </i>",
"     , MRSA, and",
"     <i>",
"      Stenotrophomonas maltophilia",
"     </i>",
"     infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Treatment of",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonitis (PCP),",
"     <i>",
"      Shigella",
"     </i>",
"     , and severe urinary tract infections (FDA approved in children and adults); has also been used in treatment of severe or complicated infections caused by susceptible bacteria when oral therapy is not feasible, including typhoid fever and",
"     <i>",
"      Nocardia asteroides",
"     </i>",
"     infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F154917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bactrim&trade; may be confused with bacitracin, Bactine&reg;, Bactroban&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Co-trimoxazole may be confused with clotrimazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Septra&reg; may be confused with Ceptaz, Sectral&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Septra&reg; DS may be confused with Semprex&reg;-D",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F154912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The most common adverse reactions include gastrointestinal upset (nausea, vomiting, anorexia) and dermatologic reactions (rash or urticaria). Rare, life-threatening reactions have been associated with co-trimoxazole, including severe dermatologic reactions, blood dyscrasias, and hepatotoxic reactions. Most other reactions listed are rare, however, frequency cannot be accurately estimated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Allergic myocarditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Apathy, aseptic meningitis, ataxia, chills, depression, fatigue, fever, hallucinations, headache, insomnia, kernicterus (in neonates), nervousness, peripheral neuritis, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity, pruritus, rash, skin eruptions, urticaria; rare reactions include erythema multiforme, exfoliative dermatitis, Henoch-Sch&ouml;nlein purpura, Stevens-Johnson syndrome, and toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (generally at high dosages), hypoglycemia (rare), hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, glottitis, nausea, pancreatitis, pseudomembranous colitis, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, eosinophilia, hemolysis (with G6PD deficiency), hemolytic anemia, hypoprothrombinemia, leukopenia, megaloblastic anemia, methemoglobinemia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity (including hepatitis, cholestasis, and hepatic necrosis), hyperbilirubinemia, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, rhabdomyolysis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, crystalluria, diuresis (rare), interstitial nephritis, nephrotoxicity (in association with cyclosporine), renal failure, serum creatinine increased, toxic nephrosis (with anuria and oliguria)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pulmonary infiltrates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, anaphylaxis, angioedema, periarteritis nodosa (rare), serum sickness, systemic lupus erythematosus (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sulfonamides, trimethoprim, or any component; porphyria; megaloblastic anemia due to folate deficiency; infants &lt;2 months of age (manufacturer&rsquo;s information), infants &lt;4 weeks of age (Pediatric HIV Opportunistic Infections Guidelines; CDC, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; dosage adjustment recommended and maintain adequate hydration to prevent crystalluria. Use with caution in patients with G-6-PD deficiency; dose-related hemolysis may occur.  Use with caution in patients with potential folate deficiency (eg, the elderly, chronic alcoholics, anticonvulsant therapy, malabsorption syndrome, and malnourished), in patients with allergies, asthma, or thyroid dysfunction. May cause hyperkalemia (associated with high doses of trimethoprim), use with caution in patients receiving potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. May cause hypoglycemia, particularly in malnourished or patients with renal or hepatic impairment. Incidence of adverse effects appears to be increased in patients with AIDS. Slow acetylators may be more prone to adverse reactions.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fatalities associated with sulfonamides, although rare, have occurred due to severe reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias; discontinue use at first sign of rash or any sign of adverse reaction, including sore throat, fever, arthralgia, pallor, purpura, jaundice, cough, shortness of breath, and pulmonary infiltrates. Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid); potential for cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. In an established infection, sulfonamides do not eradicate streptococcus nor prevent sequelae, such as rheumatic fever, and should not be used for the treatment of group A beta-hemolytic streptococcal infection. Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Sulfa antibiotics have been shown to displace bilirubin from protein binding sites which may potentially lead to hyperbilirubinemia and kernicterus in neonates and young infants; do not use in neonates; avoid use in infants &lt;2 months unless other options are not available (eg,",
"     <i>",
"      Pneumocystis",
"     </i>",
"     ). Concomitant use with leucovorin for the acute treatment of",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia in patients with HIV infection has been associated with increased rates of treatment failure and morbidity.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Oral suspension and tablets may contain sodium metabisulfites which may cause allergic reactions in susceptible individuals. Injection and oral suspension contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use forms containing propylene glycol with caution in neonates. Injection contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use products containing benzyl alcohol with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F154902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Trimethoprim may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amantadine: Trimethoprim may enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. Amantadine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Amantadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Trimethoprim may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Trimethoprim may decrease the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: Sulfamethoxazole may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: Trimethoprim may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Sulfonamide Derivatives may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Derivatives may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): May increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Dapsone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Trimethoprim may enhance the adverse/toxic effect of Dapsone (Topical). More specifically, trimethoprim may increase the risk for hemolysis",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Trimethoprim may decrease the excretion of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Trimethoprim may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Sulfonamide Derivatives may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Trimethoprim may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamiVUDine: Trimethoprim may decrease the excretion of LamiVUDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May diminish the therapeutic effect of Trimethoprim. Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for",
"     <i>",
"      Pneumocystis jiroveci",
"     </i>",
"     pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Trimethoprim may enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Memantine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: Sulfamethoxazole may enhance the myelosuppressive effect of Mercaptopurine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: Trimethoprim may enhance the myelosuppressive effect of Mercaptopurine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Trimethoprim may increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May enhance the adverse/toxic effect of Sulfonamide Derivatives. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Sulfonamide Derivatives may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (eg, bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Trimethoprim may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Sulfonamide Derivatives may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Trimethoprim may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium P-Aminobenzoate: May diminish the therapeutic effect of Sulfonamide Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Trimethoprim may increase the serum concentration of PRALAtrexate. More specifically, trimethoprim may decrease excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of trimethoprim. Monitor for decreased pralatrexate levels with discontinuation of trimethoprim.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Sulfamethoxazole may increase the serum concentration of PRALAtrexate. More specifically, sulfamethoxazole may decrease excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of sulfamethoxazole. Monitor for decreased pralatrexate levels with discontinuation of sulfamethoxazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procaine: May diminish the therapeutic effect of Sulfonamide Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Trimethoprim may decrease the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: Trimethoprim may enhance the hyperkalemic effect of Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Sulfonamide Derivatives may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Trimethoprim may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of trimethoprim, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonamide Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F154854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F154867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; therefore, the manufacturer classifies TMP-SMX as pregnancy category C. TMP-SMX crosses the placenta and distributes to amniotic fluid. Due to trimethoprim&rsquo;s potential effect on folic acid metabolism, TMP-SMX should only be used during pregnancy if the benefit justifies the potential risk. The use of dihydrofolate reductase inhibitors, including trimethoprim, during pregnancy may increase the risk of congenital anomalies including cardiovascular defects, oral clefts, urinary tract anomalies, and neural tube defects. Folic acid supplementation may decrease this risk. A few case reports have described additional congenital anomalies after TMP-SMX exposure, but none of these have proven causality. Most studies and case reports have failed to show an increased risk for congenital malformations after use of TMP-SMX. Per the manufacturer, TMP-SMX is contraindicated in late pregnancy because sulfonamides pass the placenta and may cause kernicterus in the newborn, but this has not been observed specifically with SMX. Neonatal healthcare providers should be informed if maternal sulfonamide therapy is used near the time of delivery. TMP-SMX may be used in pregnancy for prophylaxis or treatment of",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP), the prophylaxis of",
"     <i>",
"      Toxoplasmic gondii",
"     </i>",
"     encephalitis (TE), and may prevent fetal loss in patients with Q fever (",
"     <i>",
"      Coxiella burnetii",
"     </i>",
"     ). The pharmacokinetics of TMP-SMX are similar to nonpregnant values in early pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, renal function test, liver function test, urinalysis; observe for change in bowel frequency",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sulfamethoxazole interferes with bacterial folic acid synthesis and growth via inhibition of dihydrofolic acid formation from para-aminobenzoic acid; trimethoprim inhibits dihydrofolic acid reduction to tetrahydrofolate resulting in sequential inhibition of enzymes of the folic acid pathway",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Almost completely (90% to 100%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta; distributes into breast milk, joint fluid, sputum, middle ear fluid, bile, and CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TMP: 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SMX: 68%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TMP: Metabolized to oxide and hydroxylated metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SMX: N-acetylated and glucuronidated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TMP: 6-11 hours, prolonged in renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SMX: 9-12 hours, prolonged in renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Both excreted in urine as metabolites and unchanged drug",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/2/23589?source=see_link\">",
"      see \"Trimethoprim-sulfamethoxazole (co-trimoxazole): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintain adequate fluid intake unless instructed to restrict fluid intake. May cause nausea, vomiting, or GI upset. Notify physician if rash, sore throat, pallor, glossitis, fever, arthralgia, cough, shortness of breath, or jaundice occurs. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1046622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Leucovorin calcium should be given if bone marrow suppression occurs. Guidelines for prophylaxis of",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia: Initiate PCP prophylaxis in the following patients (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &bull;	 All infants born to HIV-infected mothers should be given prophylaxis with TMP-SMZ beginning at 4-6 weeks of age and continue until HIV infection has been reasonably excluded",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &bull;	 All HIV-infected infants &lt;12 months, regardless of CD4+ count or percentage, should continue prophylaxis through the first year of life and reassess based on defined thresholds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &bull;	 Children 1-5 years of age with CD4+ count &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     or CD4+ percentage &lt;15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &bull; Children &ge;6 years of age with CD4+ count &lt;200 or CD4+ percentage &lt;15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &bull; Adolescents and Adults with CD4+ count &lt;200 or oropharyngeal candidiasis",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/23/41336/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media, \"Diagnosis and Management of Acute Otitis Media,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      ,  2004, 113(5):1451-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/23/41336/abstract-text/15121972/pubmed\" id=\"15121972\" target=\"_blank\">",
"        15121972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007: 154.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/23/41336/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/23/41336/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes WT, &ldquo;",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia: New Approaches to Diagnosis, Treatment, and Prevention,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1991, 10(5):391-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/23/41336/abstract-text/2067889/pubmed\" id=\"2067889\" target=\"_blank\">",
"        2067889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jarosinki PF, Kennedy PE, and Gallelli JF, &ldquo;Stability of Concentrated Trimethoprim-Sulfamethoxazole Admixtures,&rdquo;",
"      <i>",
"       AJHP",
"      </i>",
"      , 1989, 46(4):732-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/23/41336/abstract-text/2785757/pubmed\" id=\"2785757\" target=\"_blank\">",
"        2785757",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li PK, Szeto CC, Piraino B, et al, \"Peritoneal Dialysis-Related Infections Recommendations: 2010 Update,\"",
"      <i>",
"       Perit Dial Int",
"      </i>",
"      , 2010, 30(4):393-423",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/23/41336/abstract-text/20628102/pubmed\" id=\"20628102\" target=\"_blank\">",
"        20628102",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lui C, Bayer A, Cosgrow SE, et al, &ldquo;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      Infections in Adults and Children,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011,52:1-38.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Masur H, Kaplan JE, Holmes KK, et al, \"Guidelines for Preventing Opportunistic Infections Among HIV-Infected Persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2002, 137(5 Pt 2):435-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/23/41336/abstract-text/12617574 /pubmed\" id=\"12617574 \" target=\"_blank\">",
"        12617574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nahata MC, &ldquo;Dosing Regimens of Trimethoprim/Sulfamethoxazole (TPM/SMX) in Patients With Renal Dysfunction.,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(12):1300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/23/41336/abstract-text/8672842/pubmed\" id=\"8672842\" target=\"_blank\">",
"        8672842",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paap CM and Nahata MC, \"Trimethoprim/Sulfamethoxazole Dosing During Renal Dysfunction,\"",
"      <i>",
"       Annals Pharmacother",
"      </i>",
"      , 1995, 29:1300.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Antimicrobial Agents and Related Therapy,\" 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 747. Available at file://aapredbook.aappublications.org/cgi/content/full/2009/1/4.3.1",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Drugs for Parasitic Infections,\" 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 783-816. Available at file://aapredbook.aappublications.org/cgi/content/full/2009/1/4.10",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warady BA, Schaefer F, Holloway M, et al, \"Consensus Guidelines for the Treatment of Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis,\"",
"      <i>",
"       Perit Dial Int",
"      </i>",
"      , 2000, 20(6):610-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/23/41336/abstract-text/11216549/pubmed\" id=\"11216549\" target=\"_blank\">",
"        11216549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12816 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_23_41336=[""].join("\n");
var outline_f40_23_41336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154885\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154886\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046614\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046607\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154857\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154842\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046618\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154913\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046610\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046617\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154917\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154912\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046621\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046606\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046605\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154902\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154851\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154854\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154867\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046613\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046604\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046620\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046612\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046622\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12816\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12816|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=related_link\">",
"      Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/2/23589?source=related_link\">",
"      Trimethoprim-sulfamethoxazole (co-trimoxazole): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_23_41337="Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection";
var content_f40_23_41337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/23/41337/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/23/41337/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/23/41337/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/23/41337/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/23/41337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/23/41337/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/23/41337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pegylated interferon (peginterferon) in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is the current standard of care for patients with chronic hepatitis C genotype 2, 3, or 4 who are eligible for treatment. Patients with genotype 1 should be treated with peginterferon, ribavirin, and a protease inhibitor (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will review the mechanism of action and clinical trials of peginterferon in the treatment of hepatitis C. General recommendations for the care of patients with hepatitis C, the selection of patients for antiviral treatment, a discussion of factors that influence treatment response rates, as well as specific treatment regimens are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic is also discussed in a guideline issued by the American Association for the Study of Liver Diseases. The AASLD guideline for the diagnosis, management, and treatment of hepatitis C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/1\">",
"     1",
"    </a>",
"    ], as well as other AASLD guidelines, can be accessed through the AASLD web site at",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     www.aasld.org/practiceguidelines/Pages/default.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19603107\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha interferons have been extensively studied in the treatment of patients with chronic hepatitis, including hepatitis B, C, and D. Alpha interferons are type-1 interferons and are an important part of the innate antiviral immune response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. They also play a role in the adaptive immune response. Alpha interferons have potent antiviral activity. They induce interferon-stimulated genes (ISGs) that help establish an antiviral state within cells, though the response is not virus-specific. Alpha interferons act by binding to cell surface receptors, activating a response cascade that culminates in the expression of multiple ISGs, some of which block viral protein synthesis. In addition, alpha interferon may lead to a decrease in viral RNA stability.",
"   </p>",
"   <p>",
"    In addition to their effects on the innate immune system, alpha interferons also interact with the adaptive immune system. Type-1 interferons promote the proliferation of memory T-cells, prevent T-cell apoptosis, stimulate natural killer cell activation, and stimulate dendritic cell maturation. Type-1 interferons also upregulate the production of major histocompatibility complex class-I and class-II peptides and may promote a T-helper-1 phenotype over a T-helper-2 phenotype. These activities may help to prevent immune exhaustion and enhance an adaptive immune response targeted against HCV. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE FOR PEGYLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The attachment of polyethylene glycol to a protein (pegylation) reduces its rate of absorption following subcutaneous injection, reduces renal and cellular clearance, and decreases the immunogenicity of the protein. All of these effects tend to enhance the half-life of the pegylated versus the native protein. On the other hand, pegylation may interfere with the ability of a protein to bind to its receptor, thereby decreasing its biologic effect. Thus, the true biologic effect of the pegylated protein is determined by the balance of these competing properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/4-8\">",
"     4-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potentially favorable effects of pegylation provide the rationale for the development of pegylated interferons for the treatment of hepatitis C. The higher steady-state concentrations that can be achieved with pegylated interferons were predicted to have favorable therapeutic effects based upon viral kinetic studies, a hypothesis that has been supported by the results of controlled clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two formulations of peginterferon alfa have been developed: peginterferon alfa-2a (Pegasys, Roche Pharmaceuticals), and peginterferon alfa-2b (Peg-Intron, Schering-Plough Corporation). Both are approved for treatment of HCV and are available in combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . Data suggest that there may be an advantage to treatment with peginterferon alfa-2a. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link&amp;anchor=H19310924#H19310924\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\", section on 'Choice of peginterferon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the formulations of peginterferon alfa, a formulation of peginterferon lambda has been developed and is being studied in patients with HCV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/13\">",
"     13",
"    </a>",
"    ]. Because the interferon lambda-1 receptor has a more limited distribution than the alfa receptor, peginterferon lambda may have fewer side effects. While it has been shown to have antiviral activity, sustained virologic response (SVR) rates in patients receiving peginterferon lambda have not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COMPARISON OF PEGINTERFERON WITH STANDARD INTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both forms of peginterferon have been compared with standard interferon, given alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/14-19\">",
"     14-19",
"    </a>",
"    ]. Treatment with peginterferon is superior to standard interferon with regard to achieving a sustained virologic response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=see_link&amp;anchor=H9643992#H9643992\">",
"     \"Overview of the management of chronic hepatitis C virus infection\", section on 'Goal of antiviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All studies of peginterferon suggest that quality of life is improved compared with standard interferon. However, the most significant improvement in quality of life is associated with an SVR. Because SVR rates are significantly better with peginterferon compared with standard interferon, the improvement in quality of life is related to the improvement in SVR. The use of peginterferon may also be associated with less severe side effects than standard interferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/16,20\">",
"     16,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histologic response appears to be better following treatment with peginterferon compared with standard interferon. However, this observation is a reflection of the improved response seen with peginterferon therapy, since histologic improvement occurs primarily in patients who achieve an SVR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/21-25\">",
"     21-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Peginterferon monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peginterferon monotherapy is associated with higher SVR rates compared with standard interferon. SVR rates are approximately 25 percent for patients infected with HCV genotype 1 (compared with 8 to 12 percent with standard interferon) and 54 percent for those with genotypes 2 and 3 (compared with approximately 34 percent for standard interferon). Responses also vary depending upon baseline serum HCV RNA levels (",
"    <a class=\"graphic graphic_table graphicRef68707 \" href=\"mobipreview.htm?2/34/2606\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57374 \" href=\"mobipreview.htm?12/38/12908\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/14,26,27\">",
"     14,26,27",
"    </a>",
"    ]. Response rates are lower in African Americans, although better than with standard interferon (SVR rates of 15 versus 0 percent in one report) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link&amp;anchor=H16094312#H16094312\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'African Americans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peginterferon monotherapy may have a role in patients who cannot tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (such as patients with renal failure, hemoglobinopathies, or those who develop severe anemia while on therapy). Long-term peginterferon monotherapy was evaluated as a treatment for patients with advanced fibrosis and cirrhosis who cannot achieve an SVR during combination therapy. However, two large randomized controlled trials (HALT-C and EPIC-3) found no benefit with this form of maintenance therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6411393\">",
"     'Maintenance therapy in nonresponders'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A trial with 85 patients with end-stage renal disease on hemodialysis found that 48 weeks of low-dose peginterferon monotherapy (90 to 135",
"    <span class=\"nowrap\">",
"     mcg/week)",
"    </span>",
"    resulted in SVR rates of 35 to 40 percent.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    was not given because it is renally excreted and accumulates with renal insufficiency, which can lead to severe or even catastrophic hemolysis. The majority of treated patients (75 percent) had HCV genotype 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/31\">",
"     31",
"    </a>",
"    ]. The SVR rates were similar for those who received 90",
"    <span class=\"nowrap\">",
"     mcg/week",
"    </span>",
"    and those who received 135",
"    <span class=\"nowrap\">",
"     mcg/week.",
"    </span>",
"    There were six deaths (7 percent), three of which were thought to possibly be related to the study treatment (hemorrhagic stroke, hypertrophic cardiomyopathy, and complications related to pneumonia, sepsis, and multiorgan failure). Those three deaths all occurred in the 135",
"    <span class=\"nowrap\">",
"     mcg/week",
"    </span>",
"    group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summarizes the major initial trials of combination therapy with interferon (standard or pegylated) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . The SVR rate is greatly influenced by the HCV genotype and to a lesser extent by other factors such as HCV viral load (ie, serum level of HCV RNA), and the presence of cirrhosis (",
"    <a class=\"graphic graphic_figure graphicRef56726 graphicRef79643 graphicRef67449 \" href=\"mobipreview.htm?22/44/23235\">",
"     figure 1A-C",
"    </a>",
"    ). The dose of ribavirin and compliance with therapy are also important. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6585389\">",
"    <span class=\"h3\">",
"     Interferon-naive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase III randomized controlled trial included 1530 patients who were randomly assigned to three groups, each of whom received treatment for 48 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Standard",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"       interferon alfa-2b",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      (1000 to 1200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"     </li>",
"     <li>",
"      Peginterferon alfa-2b (1.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per week for four weeks followed by 0.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per week) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      (1000 to 1200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"     </li>",
"     <li>",
"      Peginterferon alfa-2b (1.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per week) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      (800",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mean age of the study participants was 43 years. The majority were white (90 percent), were infected by genotype 1 (68 percent), and had HCV RNA titers &gt;2 million",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (68 percent). Bridging fibrosis or cirrhosis was present in 29 percent.",
"   </p>",
"   <p>",
"    The overall SVR rates for the standard, 0.5",
"    <span class=\"nowrap\">",
"     mcg/kg,",
"    </span>",
"    and 1.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    groups were 47, 47, and 54 percent, respectively. The differences were statistically significant when comparing the 1.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    dose to the lower dose of peginterferon and the standard interferon arms. The presence of cirrhosis did not appear to affect the results. The response among patients with genotype 1 was significantly higher compared with standard interferon (42 versus 33 percent). The SVR rate was approximately 80 percent in those infected with genotypes 2 and 3 for all treatment groups. A retrospective analysis of this study demonstrated that SVR rates increased with increasing doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    when expressed as milligrams of",
"    <span class=\"nowrap\">",
"     ribavirin/kg",
"    </span>",
"    of body weight, suggesting that ribavirin should be dosed according to body weight. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link&amp;anchor=H32984741#H32984741\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'Ribavirin dosing'",
"    </a>",
"    .) The response was also related to the absolute dose of ribavirin; higher doses of ribavirin were associated with an increased SVR, regardless of body weight.",
"   </p>",
"   <p>",
"    The second major study of peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    was a multicenter trial involving 1121 patients, comparing the efficacy of peginterferon alfa-2a (180 mcg SC each week) plus ribavirin (1000 to 1200 mg) with standard",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    plus ribavirin (Rebetron, Schering Plough, Kenilworth, NJ) and with peginterferon alfa-2a monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients were treated for 48 weeks. Approximately 65 percent of patients were infected with genotype 1, while 12 to 15 percent had cirrhosis. The mean HCV RNA concentration at baseline was 6 million",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"   </p>",
"   <p>",
"    An SVR was observed significantly more often in the",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    group compared with standard interferon and ribavirin (Rebetron) or peginterferon monotherapy (56 versus 44 and 29 percent, respectively). The response rate was significantly higher for patients with genotype 2 or 3 compared with genotype 1 (76 versus 46 percent). In addition, the response was higher for patients who received at least 80 percent of the dose of ribavirin and peginterferon (75 versus 48 percent).",
"   </p>",
"   <p>",
"    A third trial included 1311 patients who were randomly assigned to peginterferon alfa-2a (180 mcg SC each week) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (either 800 or 1200 mg daily) for 24 or 48 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/19\">",
"     19",
"    </a>",
"    ]. The highest SVR rate (52 percent) in those with genotype 1 was observed after 48 weeks of treatment using the higher dose of ribavirin. For patients with genotype 2 or 3, the SVR rate with the lower dose of ribavirin (800 mg daily) was the same after 24 weeks (80 percent) as those who received the higher dose of ribavirin for 48 weeks. Based upon these data, the National Institutes of Health Consensus conference recommended that patients with genotypes 2 and 3 be treated with peginterferon and the lower dose of ribavirin, 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for only 24 weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link&amp;anchor=H488642640#H488642640\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\", section on 'Genotype 2 or 3'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12156576\">",
"    <span class=\"h3\">",
"     Retreatment of prior nonresponders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of retreatment of patients who previously failed attempts at eradication HCV is variable. In general, patients are more likely to attain an SVR if they were previously treated with standard interferon or if they relapsed following prior treatment attempts (as opposed to not responding to the treatment). The following summarizes major clinical studies of retreatment approaches using peginterferon-based regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefit of retreating patients who failed treatment with interferon-based therapy was evaluated in an initial report from the HALT-C trial that focused on the first 604 patients who had been enrolled [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/32\">",
"       32",
"      </a>",
"      ]. All patients were HCV RNA positive, had bridging fibrosis or cirrhosis, and had previously not responded to interferon-based treatment with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      . Patients were retreated with peginterferon alfa-2a (180 mcg weekly) plus ribavirin (1000 to 1200",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      Those without detectable HCV RNA at week 20 were continued on therapy for a total of 48 weeks and then followed for an additional 24 weeks.",
"      <br/>",
"      <br/>",
"      Thirty-five percent of patients had undetectable HCV RNA at 20 weeks and continued on therapy. Of these, 109 (18 percent on intention-to-treat analysis) achieved an SVR. Independent variables associated with an SVR included prior treatment with interferon monotherapy (28 versus 12 percent), infection with genotypes 2 or 3 (54 to 65 versus 17 percent), baseline HCV RNA levels less than 1.5 million",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"      (27 versus 15 percent), an AST:ALT ratio less than 1.0 (21 versus 6 percent), and the absence of cirrhosis on liver biopsy (23 versus 11 percent).",
"      <br/>",
"      <br/>",
"      The SVR rate was significantly lower in those who received &le;60 percent of the starting dose of ribavirin during the first 20 weeks of treatment compared with those who received &ge;80 percent (11 versus 21 percent). By contrast, there was no significant decline in SVR rates in those in whom the dose of peginterferon or ribavirin was reduced after 20 weeks of therapy.",
"     </li>",
"     <li>",
"      The efficacy of combination therapy in patients treated with prior interferon-based therapy was evaluated in a study that included 182 patients who did not achieve an SVR after treatment with interferon monotherapy or combination therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      (approximately 80 percent of patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/33\">",
"       33",
"      </a>",
"      ]. Patients were treated with peginterferon alfa-2b plus ribavirin for 48 weeks. The SVR was 20 percent in previous nonresponders and 55 percent in previous relapsers. Among previous nonresponders, SVR was significantly higher in those infected with genotypes 2 and 3 compared with genotype 1 (57 versus 17 percent). Among previous relapsers, response rates were similar for genotypes 2 and 3 versus 1 (59 versus 53 percent). A similar SVR (20 percent) in",
"      <span class=\"nowrap\">",
"       interferon/ribavirin",
"      </span>",
"      nonresponders was observed in a later report of 141 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study focused on 321 patients who were randomly assigned to one of two combination regimens: Peginterferon alfa-2b (1.0",
"      <span class=\"nowrap\">",
"       mcg/kg)",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      (1000 to 1200 mg per day) or peginterferon alfa-2b (1.5",
"      <span class=\"nowrap\">",
"       mcg/kg)",
"      </span>",
"      plus ribavirin (800 mg per day) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/35\">",
"       35",
"      </a>",
"      ]. Patients were treated for 48 weeks, with cessation of therapy if HCV RNA was positive at week 24. The overall SVR rate was 16 percent. However, the rate varied depending upon the prior treatment and response (8 percent in combination therapy nonresponders, 21 percent in interferon monotherapy nonresponders, and 42 percent in combination therapy relapsers). In nonresponders to prior combination therapy, HCV RNA levels &lt;100,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      at the end of the prior treatment course were associated with an increased SVR rate compared with higher levels (21 versus 5 percent). Genotype 1 was associated with a significantly lower overall SVR rate (14 versus 33 percent). The response rate was also significantly lower in African Americans (4 versus 18 percent).",
"     </li>",
"     <li>",
"      A fourth study included 950 patients who had not responded to 12 or more weeks of peginterferon alfa-2b plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      and who were randomly assigned to retreatment in one of four groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/36\">",
"       36",
"      </a>",
"      ]: Group A received peginterferon alfa-2a (360 micrograms per week for 12 weeks then 180 micrograms per week) to complete 72 weeks; Group B received peginterferon alfa-2a (360 micrograms per week for 12 weeks then 180 micrograms per week) to complete 48 weeks; Group C received peginterferon alfa-2a (180 micrograms per week) for 72 weeks; Group D received peginterferon alfa-2a (180 micrograms per week) for 48 weeks. All groups also received ribavirin (1000 or 1200 mg daily based on weight).",
"      <br/>",
"      <br/>",
"      The SVR rates were 16, 7, 14, and 9 percent in groups A to D, respectively. Extended treatment duration significantly increased SVR rates (16 percent for 72 weeks in groups A and C versus 8 percent for 48 weeks in groups B and D). Complete viral suppression (HCV RNA &lt;50",
"      <span class=\"nowrap\">",
"       IU/mL)",
"      </span>",
"      at 12 weeks was predictive of SVR. SVR rates overall were 49 percent in those who achieved complete viral suppression versus only 4 percent in those who did not. Thus, overall SVR rates with retreatment were low, but highest with retreatment for 72 weeks compared with 48 weeks. Similar to the treatment-naive setting, SVR rates were predicted by complete viral suppression at week 12.",
"     </li>",
"     <li>",
"      A fifth trial included a total of 2333 patients with chronic HCV and significant fibrosis who previously failed treatment with standard interferon or peginterferon plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      and were retreated with peginterferon alfa-2b plus weight-based ribavirin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/37\">",
"       37",
"      </a>",
"      ]. The overall rate of SVR was 22 percent. Rates of SVR were higher in prior relapsers versus nonresponders (38 versus 14 percent) regardless of previous treatment, and in patients who were previously treated with standard interferon plus ribavirin compared with peginterferon plus ribavirin (25 versus 17 percent). Predictors of a response included an undetectable HCV RNA at week 12, genotype 2 or 3, a lower fibrosis score, and baseline viral load &le;600,000",
"      <span class=\"nowrap\">",
"       IU/mL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6585075\">",
"    <span class=\"h3\">",
"     Use in patients with portal hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have included patients with compensated cirrhosis and portal hypertension. A controlled trial that focused on this population included 102 patients with compensated cirrhosis who had portal hypertension (defined by the presence of varices, an enlarged spleen, or low platelet count) who were randomly assigned to combination therapy or peginterferon monotherapy for up to 52 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/38\">",
"     38",
"    </a>",
"    ]. The SVR rate was significantly higher in the combination therapy group (22 versus 10 percent) and was more likely with genotype 2 or 3 compared with genotype 1 (67 versus 11 percent). Patients who achieved an SVR were less likely to develop worsening liver disease during follow-up. Overall, 33 patients (one-third of the group) dropped out due to adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    tested these drugs in combination for a duration of 48 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/17\">",
"     17",
"    </a>",
"    ]. It soon became apparent that patients with HCV genotype 2 or 3 could be treated for shorter periods of time. Several subsequent studies have aimed at determining the optimal duration of therapy for patients in various categories. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H12156576\">",
"     'Retreatment of prior nonresponders'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148834010#H148834010\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Treatment regimens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6409509\">",
"    <span class=\"h2\">",
"     Genotype",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6585095\">",
"    <span class=\"h3\">",
"     Genotype 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with genotype 1 who are treated with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    alone have sustained virologic response rates of 40 to 50 percent with combination therapy with 48 weeks of treatment. However, significantly higher sustained virologic response rates have been seen with the addition of a protease inhibitor (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    ) to the treatment regimen. Although protease inhibitors have potent antiviral activity against HCV, viral resistance develops rapidly when they are used as monotherapy. However the addition of peginterferon (and RBV) is thought to overcome this problem as these standard agents are effective in eliminating the resistant variants, whereas the wild-type virus is effectively dealt with by the protease inhibitor. Treatment regimens used to treat patients with genotype 1 are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148834010#H148834010\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Treatment regimens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15785?source=see_link\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6409570\">",
"    <span class=\"h3\">",
"     Genotypes 2 and 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current guidelines recommend 24 weeks of therapy using a lower dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (800 mg daily in divided doses), which appears to be as effective as longer courses of therapy using the standard higher dose of ribavirin in patients infected with genotype 2 and 3. Data on even shorter periods of treatment are contradictory; thus, routine treatment for less than 24 weeks cannot be recommended, although such an approach has been suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/39-42\">",
"     39-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest randomized controlled trial to evaluate this approach included 1469 patients with genotype 2 or 3 who received peginterferon plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for 16 or 24 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/43\">",
"     43",
"    </a>",
"    ]. The study showed that the SVR rate was significantly lower in patients treated for 16 weeks compared with 24 weeks of treatment (62 versus 70 percent). In addition, the relapse rate was significantly higher in the 16 week group (31 versus 18 percent). In a subset analysis of patients with pretreatment serum HCV RNA levels of 400,000 IU per mL or less, the SVR rates were similar in the groups treated for 16 and 24 weeks (82 versus 81 percent). Among those with a rapid virologic response (ie, undetectable HCV RNA by week 4), the SVR rate was significantly lower in the 16 week group (79 versus 85 percent). These data suggest that treatment of patients with genotype 2 or 3 for 16 weeks leads to a lower overall SVR rate than treatment for 24 weeks.",
"   </p>",
"   <p>",
"    A subsequent randomized controlled trial evaluated 14 versus 24 weeks of therapy in patients with genotype 2 or 3 infection who achieved a rapid virologic response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/44\">",
"     44",
"    </a>",
"    ]. Response rates were similar in the 14 and 24 week groups (86 versus 93 percent), but a statistically significant difference could not be excluded. The authors speculated that the shorter course of therapy might be cost-effective, although they did not perform a formal cost-effectiveness analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6409805\">",
"    <span class=\"h3\">",
"     Genotype 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forty-eight weeks of treatment has generally been recommended for patients infected with genotype 4 (common in persons who became infected while in Egypt, the Middle East, several eastern Mediterranean countries, and in north-eastern Poland), which is also associated with relatively lower response rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The accuracy of predicting a response in patients with genotype 4 based upon the decline in HCV RNA titer has not been as well established as for genotype 1, but is probably similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link&amp;anchor=H488642654#H488642654\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\", section on 'Treatment regimens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link&amp;anchor=H488641848#H488641848\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\", section on 'Monitoring viral load during therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link&amp;anchor=H32984769#H32984769\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'Changes in viral load during treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study suggested that shorter duration treatment may be sufficient in patients who achieve undetectable HCV RNA at weeks 4 and 12 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6409812\">",
"    <span class=\"h3\">",
"     Genotype 5",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCV genotype 5 (seen predominantly in persons who became infected while in South Africa) appears to have similar responsiveness as genotypes 2 and 3 after a 48-week course of combination therapy (SVR of approximately 64 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6409819\">",
"    <span class=\"h3\">",
"     Genotype 6",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response rates with genotype 6 (seen primarily in south China, Hong Kong, Taiwan, Macao and Southeast Asia) appear to be better than with genotype 1, but less than genotypes 2 and 3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Data regarding the optimal duration of therapy are contradictory:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study of 190 Asian-American patients with genotype 6 suggested that patients should be treated for 48 rather than 24 weeks; the SVR rate for those treated with peginterferon plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      was significantly higher with 48 versus 24 weeks of therapy (75 versus 39 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial with 60 patients examined the effect of treatment duration with combination therapy on SVR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/55\">",
"       55",
"      </a>",
"      ]. Patients were assigned to receive either 24 or 48 weeks of treatment with peginterferon plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      . SVR rates did not differ significantly between those treated for 24 weeks and those treated for 48 weeks (70 versus 79 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6411393\">",
"    <span class=\"h2\">",
"     Maintenance therapy in nonresponders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have suggested that interferon-based treatments may be associated with clinical improvement, even in patients who do not achieve an SVR. In particular, histologic and biochemical improvement have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/56\">",
"     56",
"    </a>",
"    ]. Some studies have also suggested a reduction in the incidence of hepatocellular carcinoma, although the strength of this association is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35768?source=see_link&amp;anchor=H11#H11\">",
"     \"Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection\", section on 'Prevention of hepatocellular carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations led to the development of large, multicenter trials evaluating long-term treatment with peginterferon monotherapy in patients who did not respond to prior interferon-based therapies (HALT-C, EPIC-3, COPILOT, and PROFI-C) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/32,58\">",
"     32,58",
"    </a>",
"    ]. A meta-analysis that included HALT-C, EPIC-3, and five smaller trials did not find a difference in all cause mortality or hepatic mortality with long-term, low-dose peginterferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Final results of the HALT-C trial (evaluating low-dose peginterferon alfa-2a) were negative; long-term maintenance therapy did not halt liver disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/29\">",
"     29",
"    </a>",
"    ]. The rate of disease progression was 34 percent in both groups, despite a significant decrease in serum ALT and HCV RNA levels in the group randomized to long-term interferon. Thus, the HALT-C trial does not support long-term use of interferon in patients with advanced fibrosis who did not respond to standard treatment with interferon plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . Subsequent analyses have also been published based upon the HALT-C trial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One analysis found a decreased risk of hepatocellular carcinoma with long-term maintenance therapy in patients with cirrhosis (but not those with advanced fibrosis without cirrhosis) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/57\">",
"       57",
"      </a>",
"      ]. After seven years of follow-up, the cumulative rate of hepatocellular carcinoma was lower in patients with cirrhosis who received long-term maintenance therapy compared with those who did not (8 versus 24 percent, hazard ratio 0.45, 95% CI 0.24 to 0.83).",
"     </li>",
"     <li>",
"      Another analysis found that there was excess mortality in the patients who received maintenance peginterferon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/60\">",
"       60",
"      </a>",
"      ]. After seven years of follow-up, the cumulative mortality in the treatment group was 20 percent, compared with 15 percent in the control group. While liver-related mortality was similar between the groups, there was an increase in nonliver-related deaths in the treatment group. The increased mortality was primarily seen in patients with advanced fibrosis but not cirrhosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The final results of the other long-term trials have not yet been published. The COPILOT study included 534 patients who were randomly assigned to long-term treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    or peginterferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/58\">",
"     58",
"    </a>",
"    ]. An interim report found that after two years, the risk of progression of the Child-Turcotte-Pugh score was significantly reduced, and significantly fewer patients in the peginterferon group developed variceal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/58\">",
"     58",
"    </a>",
"    ]. The decline in the Child-Turcotte-Pugh score appeared to occur only in patients who developed variceal bleeding.",
"   </p>",
"   <p>",
"    An interim report of a second trial, EPIC-3, had similar results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/30\">",
"     30",
"    </a>",
"    ]. In that trial, 631 patients were randomized to long-term, low-dose peginterferon or observation. There was no difference between the groups with regard to the primary outcome, which was defined as the time to first clinical event (liver decompensation, development of hepatocellular carcinoma, death, or liver transplantation). Secondary analyses revealed that patients in the treatment arm had lower rates of progression to Child-Pugh class B cirrhosis, variceal development, and enlargement of pre-existing varices.",
"   </p>",
"   <p>",
"    The benefits on variceal development, enlargement, and bleeding after such a short period are a bit surprising and raise the possibility that the peginterferon may have led to a reduction in portal pressure directly. It is also possible that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    increased the risk of bleeding, although such an association has not previously been demonstrated. Furthermore, treatment for two years in a later controlled trial involving 102 patients was not associated with a benefit in complication-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/23/41337/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19602370\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects associated with peginterferon are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=see_link\">",
"       \"Patient information: Hepatitis C (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/4/17478?source=see_link\">",
"       \"Patient information: Hepatitis C (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conclusions can be drawn from the available data on peginterferons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both preparations of peginterferon appear to be superior to standard interferon with respect to sustained virologic response (SVR) rate (",
"      <a class=\"graphic graphic_figure graphicRef56726 graphicRef79643 graphicRef67449 \" href=\"mobipreview.htm?22/44/23235\">",
"       figure 1A-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Comparison of peginterferon with standard interferon'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both forms of peginterferon are superior to standard interferon in groups that typically have a poor response to standard interferon monotherapy (such as patients with genotype 1, African Americans, and those with cirrhosis). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Comparison of peginterferon with standard interferon'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link\">",
"       \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peginterferon monotherapy appears to be better tolerated than standard interferon monotherapy or combination therapy with standard interferon plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Peginterferon monotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Quality of life during treatment appears to be better with peginterferon monotherapy or combination therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      compared with standard interferon or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"       interferon alfa-2b",
"      </a>",
"      plus ribavirin combination therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Comparison of peginterferon with standard interferon'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peginterferon plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      may be effective for patients who failed prior interferon-based treatment, particularly those who relapsed to prior combination therapy with standard interferon plus ribavirin or after standard interferon monotherapy, and in those with non type-1 genotypes. (See",
"      <a class=\"local\" href=\"#H12156576\">",
"       'Retreatment of prior nonresponders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General recommendations for care of patients with hepatitis C as well as specific treatment regimens are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=see_link\">",
"       \"Overview of the management of chronic hepatitis C virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link\">",
"       \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link\">",
"       \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/1\">",
"      Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/2\">",
"      Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997; 112:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/3\">",
"      Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/4\">",
"      Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977; 252:3578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/5\">",
"      Abuchowski A, McCoy JR, Palczuk NC, et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977; 252:3582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/6\">",
"      He XH, Shaw PC, Tam SC. Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. Life Sci 1999; 65:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/7\">",
"      Katre NV. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J Immunol 1990; 144:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/8\">",
"      Shiffman ML. Pegylated interferons: what role will they play in the treatment of chronic hepatitis C? Curr Gastroenterol Rep 2001; 3:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/9\">",
"      Zeuzem S. Clinical implications of hepatitis C viral kinetics. J Hepatol 1999; 31 Suppl 1:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/10\">",
"      Layden TJ, Mika B, Wiley TE. Hepatitis C kinetics: mathematical modeling of viral response to therapy. Semin Liver Dis 2000; 20:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/11\">",
"      Zeuzem S, Schmidt JM, Lee JH, et al. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/12\">",
"      Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/13\">",
"      Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010; 52:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/14\">",
"      Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/15\">",
"      Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000; 32:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/16\">",
"      Feagan BG, Trepo C, Lindsay KL, et al. The impact of pegylated interferon alfa-2b on health-related quality of life in chronic hepatitis C patients (abstract). Hepatology 2000; 32:307A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/17\">",
"      Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/18\">",
"      Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/19\">",
"      Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/20\">",
"      Perrillo RP, Thuluvath PJ, Rothstein K, et al. Improved work productivity, safety, and quality of life with pegylated (40 kd) interferon alfa-2A (Pegasys) therapy in the treatment of chronic hepatitis C (abstract). Hepatology 2000; 32:362A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/21\">",
"      Balart LA, Lee SS, Shiffman M, et al. Histologic improvement following treatment with once weekly pegylated interferon alfa-2a (PEGASYS) and thrice weekly interferon alfa-2a (Roferon) in patients with chronic hepatitis C and compensated cirrhosis (abstract). Gastroenterology 2000; 118:A961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/22\">",
"      Heathcote EJ, Shiffman ML, Balart LA et al. Pegylated (20 kd) interferon alfa-2a (Pegasys) is superior to interferon alfa-2a (Roferon-A) in improving posttreatment histologic outcome in chronic hepatitis C patients 1584 (abstract). Hepatology 2000; 32:223A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/23\">",
"      Pockros PJ, Carithers R, Desmond P, et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 2004; 99:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/24\">",
"      Camm&agrave; C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/25\">",
"      Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/26\">",
"      Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/27\">",
"      Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/28\">",
"      Shiffman ML, Mills P, Moonka DK, et al. Enhanced efficacy of pegylated (40 kd) interferon alfa-2A (Pegasys) compared with interferon alfa-2A (Roferon-A) for chronic hepatitis C in blacks (abstract). Hepatology 2000; 32:348A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/29\">",
"      Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/30\">",
"      Bruix J, Poynard T, Colombo M, et, al. Final results of the EPIC3 cirrhosis maintenance trial: Pegintrol maintenance therapy in chirrhotic (METAVIR F4) HCV patients, who failed to resond to interferon/ribavirin (IR) therapy. Gastroenterology 2009; 136:A798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/31\">",
"      Peck-Radosavljevic M, Boletis J, Besisik F, et al. Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol 2011; 9:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/32\">",
"      Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/33\">",
"      Krawitt EL, Ashikaga T, Gordon SR, et al. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol 2005; 43:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/34\">",
"      Taliani G, Gemignani G, Ferrari C, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 2006; 130:1098.",
"     </a>",
"    </li>",
"    <li>",
"     Jacobson IM, Ahmed F, Russo MW, et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial of prior nonresponders to intereron monotherapy or combination therapy and in combination therapy relapsers: Final results. (Abstract). Gastroenterology 2003; : Abstract ID 103196.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/36\">",
"      Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/37\">",
"      Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/38\">",
"      Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007; 47:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/39\">",
"      Dalgard O, Bj&oslash;ro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/40\">",
"      Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/41\">",
"      Mangia A, Minerva N, Bacca D, et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009; 49:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/42\">",
"      Diago M, Shiffman ML, Bronowicki JP, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology 2010; 51:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/43\">",
"      Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/44\">",
"      Dalgard O, Bj&oslash;ro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/45\">",
"      Legrand-Abravanel F, Nicot F, Boulestin A, et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 2005; 77:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/46\">",
"      Derbala M, Amer A, Bener A, et al. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005; 12:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/47\">",
"      Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/48\">",
"      Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology 2007; 46:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/49\">",
"      Bonny C, Roche C, Randle K, et al. Treatment of interferon-naive patients with HCV genotype 5 with intereron (or PEG-interferon) plus ribavirin results in a very high sustained virologic response (abstract). J Hepatol 2003; 38:738A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/50\">",
"      Legrand-Abravanel F, Sandres-Saun&eacute; K, Barange K, et al. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis 2004; 189:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/51\">",
"      Dev AT, McCaw R, Sundararajan V, et al. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002; 36:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/52\">",
"      Hui CK, Yuen MF, Sablon E, et al. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 2003; 187:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/53\">",
"      Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005; 3:S97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/54\">",
"      Nguyen MH, Trinh HN, Garcia R, et al. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008; 103:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/55\">",
"      Lam KD, Trinh HN, Do ST, et al. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology 2010; 52:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/56\">",
"      Pockros PJ, Hamzeh FM, Martin P, et al. Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology 2010; 52:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/57\">",
"      Lok AS, Everhart JE, Wright EC, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011; 140:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/58\">",
"      Afdhal N, Frelich B, Levine R, et al. Colchicine versus PEG-Intron long term (COPILOT) trial: interim analysis of clinical outcomes at year 2 (abstract). Hepatology 2004; 40:239A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/59\">",
"      Koretz RL, Pleguezuelo M, Arvaniti V, et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database Syst Rev 2013; 1:CD003617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/60\">",
"      Di Bisceglie AM, Stoddard AM, Dienstag JL, et al. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 2011; 53:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/23/41337/abstract/61\">",
"      Fartoux L, Degos F, Tr&eacute;po C, et al. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol 2007; 5:502.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3643 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_23_41337=[""].join("\n");
var outline_f40_23_41337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H44\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19603107\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE FOR PEGYLATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COMPARISON OF PEGINTERFERON WITH STANDARD INTERFERON",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Peginterferon monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6585389\">",
"      - Interferon-naive patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12156576\">",
"      - Retreatment of prior nonresponders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6585075\">",
"      - Use in patients with portal hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6409509\">",
"      Genotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6585095\">",
"      - Genotype 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6409570\">",
"      - Genotypes 2 and 3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6409805\">",
"      - Genotype 4",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6409812\">",
"      - Genotype 5",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6409819\">",
"      - Genotype 6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6411393\">",
"      Maintenance therapy in nonresponders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19602370\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3643\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3643|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/42/18094\" title=\"figure 1A\">",
"      SVR genotype AASLD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/37/42590\" title=\"figure 1B\">",
"      SVR dose genotype AASLD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/42/34478\" title=\"figure 1C\">",
"      SVR genotype viral load AASLD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3643|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/34/2606\" title=\"table 1\">",
"      Virologic response Peg Intron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/38/12908\" title=\"table 2\">",
"      Efficacy peg IFN alfa 2a",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35768?source=related_link\">",
"      Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=related_link\">",
"      Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15785?source=related_link\">",
"      Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_23_41338="Gottron papules";
var content_f40_23_41338=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63383%7EDERM%2F56879%7EDERM%2F68649%7EDERM%2F54230%7EDERM%2F59545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63383%7EDERM%2F56879%7EDERM%2F68649%7EDERM%2F54230%7EDERM%2F59545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gottron's papules in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple violaceous, scaly papules are present overlying the joints on the dorsal hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heliotrope eruption in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous erythema is present on the periorbital skin in this patient with dermatomyositis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatomyositis - heliotrope eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous erythema and edema is present on the upper eyelid in this patient with dermatomyositis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Confluent areas of violaceous erythema are present on the neck, chest, and upper arms of this patient with dermatomyositis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dilated capillary loops at the proximal nail fold in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_23_41338=[""].join("\n");
var outline_f40_23_41338=null;
var title_f40_23_41339="Complications of IPF or its Rx";
var content_f40_23_41339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of idiopathic pulmonary fibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Progressive respiratory failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mortality - 39 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Findings suggestive of disease progression are multiple and nonspecific",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Bronchogenic carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mortality - 10 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Excess risk of 14:1 compared to general population; same histologic distribution as seen in population",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Cardiovascular disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mortality - 24 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Right ventricular hypertrophy, cor pulmonale due to progressive, longstanding pulmonary hypertension and right heart failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Left ventricular heart failure usually due to concurrent ischemic heart disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pulmonary infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mortality - 2 to 4 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased incidence; glucocorticoid and cytotoxic therapy may further increase risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pneumothorax",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Occurs less often than in other interstitial lung disease - &lt;10 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pulmonary embolism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mortality 3 to 7 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pulmonary angiography frequently required to make diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Complications of therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       See text",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Panos, RJ, Mortenson, RL, Niccoli, SA, King TE Jr, Am J Med 1990; 88:396.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_23_41339=[""].join("\n");
var outline_f40_23_41339=null;
var title_f40_23_41340="LMWH versus oral anticoagulants hip";
var content_f40_23_41340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical trials comparing low molecular weight heparin with oral anticoagulants in hip replacement",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Design",
"       </td>",
"       <td class=\"subtitle1\">",
"        Regimens",
"       </td>",
"       <td class=\"subtitle1\">",
"        All DVT, n/n",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Proximal DVT*, n/n",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Occurrence of major bleeding, n/n",
"        <br/>",
"        (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        N Engl J Med 1993; 329:1370",
"       </td>",
"       <td rowspan=\"2\">",
"        Randomized double-blind; bilateral venogram",
"       </td>",
"       <td>",
"        Tinzaparin 75 Xa units/kg sc once daily vs",
"       </td>",
"       <td>",
"        69/332 (21)",
"       </td>",
"       <td>",
"        16/332 (5)",
"       </td>",
"       <td>",
"        11/398 (2.8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warfarin sodium (INR 2.0-3.0)",
"       </td>",
"       <td>",
"        79/340 (23)",
"       </td>",
"       <td>",
"        13/340 (4)",
"       </td>",
"       <td>",
"        6/397 (1.5)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Thromb Haemost 1995; 74:1428",
"       </td>",
"       <td rowspan=\"2\">",
"        Randomized single-blind; bilateral venogram",
"       </td>",
"       <td>",
"        Nadroparin 60 Xa units/kg sc once daily vs",
"       </td>",
"       <td>",
"        27/195 (14)",
"       </td>",
"       <td>",
"        12/195 (6)",
"       </td>",
"       <td>",
"        3/195 (1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acenocoumarol (INR 2.0-3.0)",
"       </td>",
"       <td>",
"        27/196 (14)",
"       </td>",
"       <td>",
"        9/196 (5)",
"       </td>",
"       <td>",
"        7/196 (3.6)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        J Bone Joint Surg Am 1997; 79:1365",
"       </td>",
"       <td rowspan=\"2\">",
"        Randomized single-blind; bilateral venography",
"       </td>",
"       <td>",
"        Dalteparin 2500&nbsp;international units&nbsp;pre- and post-surgery then 5000&nbsp;international units&nbsp;sc once daily vs",
"       </td>",
"       <td>",
"        28/192 (15)",
"       </td>",
"       <td>",
"        10/192 (5)",
"       </td>",
"       <td>",
"        6/271 (2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warfarin sodium (INR 2.5) begun pre-surgery",
"       </td>",
"       <td>",
"        49/190 (26)",
"       </td>",
"       <td>",
"        16/190 (8)",
"       </td>",
"       <td>",
"        4/279 (1)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Arch Intern Med 2000; 160:2199",
"       </td>",
"       <td rowspan=\"3\">",
"        Randomized double-blind; bilateral venography",
"       </td>",
"       <td>",
"        Dalteparin 2500&nbsp;international units pre- and post-surgery, then 5000&nbsp;international units qd vs",
"       </td>",
"       <td>",
"        37/337 (11)",
"       </td>",
"       <td>",
"        3/354 (0.8)",
"       </td>",
"       <td>",
"        10/496 (2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dalteparin 2500&nbsp;international units post-surgery, then 5000&nbsp;international units qd vs",
"       </td>",
"       <td>",
"        44/336 (13)",
"       </td>",
"       <td>",
"        3/358 (0.8)",
"       </td>",
"       <td>",
"        5/487 (1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warfarin sodium (INR 2.0-3.0) begun post-surgery",
"       </td>",
"       <td>",
"        81/338 (24)",
"       </td>",
"       <td>",
"        11/363 (3)",
"       </td>",
"       <td>",
"        8/489 (1.6)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DVT: deep vein thrombosis; INR: international normalized ratio; sc: subcutaneously.",
"     <br>",
"      * Popliteal, femoral, or iliac vein thrombosis.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_23_41340=[""].join("\n");
var outline_f40_23_41340=null;
var title_f40_23_41341="Contents: Hematology calculators";
var content_f40_23_41341=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?0/37/606\">",
"       Calculators",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hematology calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hematology calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/30/1505\">",
"           Calculator: DVT probability: Wells score system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/24/35201\">",
"           Calculator: International Prognostic Index for non-Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/32/4609\">",
"           Calculator: International Prognostic Score in Hodgkin Lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/56/23425\">",
"           Calculator: MDACC Myelodysplastic syndrome prognostic model",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/14/9441\">",
"           Calculator: Myelodysplastic syndrome international prognostic scoring system (Original IPSS)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/55/39792\">",
"           Calculator: Polycythemia vera diagnostic criteria (Original PVSG diagnostic criteria)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/54/42849\">",
"           Calculator: Revised International Prognostic Scoring System (IPSS-R) in myelodysplastic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/34/30241\">",
"           Calculator: Sokal score for chronic myeloid leukemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/1/12305\">",
"           Calculator: Absolute neutrophil count",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/21/24914\">",
"           Calculator: Mantle Cell Lymphoma International Prognostic Index (MIPI)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-FE488E6DFF-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f40_23_41341=[""].join("\n");
var outline_f40_23_41341=null;
var title_f40_23_41342="Tension hemothorax PA";
var content_f40_23_41342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of tension hemothorax after pneumonectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 258px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAECATQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5rtreWeaOJVDO7BFGcck4Fdk/gKewnaLWdW0XTpV+9HNdbnX6hawbdNk8cnI2Or/kQa9l+JHw0N74xvNTbxD4e0221DZOi31yY5BlFB+XHIyOtAHk/ifw/caA9sbiSCe0ukMltd2774p174PYjuKw1RHGAwyOnvXp/wAW9Lg8L6ToHg4Ttd3en+beXNwIykZM3IVM84GD/nivLXi2sD+tABLAQD3FQSRsATFz/nirsJZRvb7g9e9SRqkvKcN6GgDLiXAG/wC/057VKEYkbSCCMjitEwB1wy/Q1GbIgZBYr7daAK5icgYIzx71F5Um08ZwSBj1rThty05MowG6Buv4VOtjg/KhAHJbNAGN5EwGGA44qxFaMSCWAz0GKvrbxLlpZPwHrT/Mh3YANAFRYFyOS3PQVMkBLDC++KnNxEoHJGani2zDhxn2oApiP5sGrEMJOQMg+/epJImLZycjvVm3cYCSDDdqAC1ikRclcitKd447Ul0UqOcY5+lNg+WNl9ehqpqFysSFcjB4IxQBn3lzFOgPkIhBxhR2pdOjh83JBU4qtPKjMDHkeuau6eCSWGRxQBdnjCj72Cex61kTsQ7YrZk2sCWUk/Xk1nXCAZPfNAGVMjPkqagdSE7fjWuyGRSMY44xVb7MM4LAGgDLkUmPnpis+XcGOev866SWzYrwwx+VU5bFmUqV57EUAYe4+tKGYdDirUlm6PhgQR7Uq23IGCfp3oAgG8rxkikQO5wuTWxBYttHmZA9KsC1xxGuKAMhISn3jub0qwkOF3ykKo55qzKqWwyOXrOmLynLn8KAHSXmMrAu0f3j1NMVJpjwc+9LHGT+Fa0MeyEbRx1J9aAMgxSDAJ6UgR8DkVstHmPLdc0iWocjAOKAMxInc4Wr1vasB8oyfWtGKx6BCMVcWDau0AcUAcZqaFL6RT1GP5CipddAGqzgdPl/9BFFAHYy2ikMyqASDkV3vxgNvfz+GNRBSQ3OjRB+QSCvBB/M1z1zpdwB8sbHngrzVWTS7nPypk+npQB1muazp3if4d2f9q3CR+IdFPkxs4+a7gOMDPcqB+nvXmMtmJH3IowOeelbzWYhBF2+30A5P5Vm3k6L8kQwP1P1oAzLlFVdg6DgVCq7R8vH0q1KAzjAoSEsdq9aAH2sgdlR1yT0IrWtrUIAy4dv0FRW1rhMIOo5c8ZqeS7j05NqnzJe+eg+lACzQQghpATL246Vl36zMe5QelTS3/2n+La3XGKY8mwYMo+nWgDLYFjnI/OhwQhxtz9asyC2ccMyt14FULnCEHBKjvQAxwVXllJpqvIpBRjnrTWlWZ8KQCRipEVl+Ug47H0oA0bO+cALMm4DuK2IFimQMDjBrnIQynI6etalg2G4Jx3HpQB0+nwFWEcgVlP8qbqBgjmRjBGxb5RuGQP9r60yyk2+WSThRnnvVC8u0cje47kZ5oApSwQzMdybW77e9aFjahYSyZCj171no/mScD8jW1aDFng8jOQKAM+5kxnJwvbFVgu9enHuauXRyzfKFA4HGaYFATPLNjv0FAEBhzFwwUY5J4qmyxKx+bP0GauvbvL1Jz2BFJ9gk7DP0oArLLGpG5WK1MI4JCGRtuexpVsZW4CMTVu0sRG2Jj+AoArvYGdeFz6HtUS6bHEcgfP6Gtvy2j4hyo9ulMcxkA3A2MON4HH4igDCeNskMMY/SopZdo2oQT3NaWoLu+XopHDr3/8ArVkyQtGcMM56EdDQBDJCGGetVHt/Tg1ooSDyKnEUcg+fg+ooAx0g5yau2sgjHlsoZSehHSrg05icpLGR7nBqZLFo24wffIoAia1LYc/cPTb0qeCDco44rTsoVgx9qZREeqE9f8KuNFbRmNoAXjb7jHjHtigCpbWxI+7gfyqC/ZYlIQcmt62ZWgmU8E85rmrwlmYnJP0oA4rWv+QnN/wH/wBBFFLrn/IUm/4D/wCgiigD2K5v1sA0EJLMRhsmse8vJmJ3yswPSqbzFmJznJqIycEE/L/KgBlxKWHrVB1JfParEpIJzilihZjheSe2KAK8cZY4xk+latpZBQN3LHkj0qW2thGhYkDA5c9BVW91HOI7fhf73c0ASXt4kACKefbrXL3t6ztlcDJ7VYuXZiT1NZLglFwCTQA1pnZvvGrUF2QAG+YetVApAOSMniiPAIyaANUskoJQ/hUT7wpA6+lV43VCSByferwuEZAGjU570AZ5VGJLrtI7rU0YfbiORXHowwcVNJChBK42ng4pI7dkBZfmHY0AWbaJ36LjHUdq1LWCRGUqCPwrJiLAjZnNbmjs7EZOCDQB0NhawS2sjOgDKvI9M1Uu9HsFt1RJ3aUnLE/w8dq2GLJacbcHbkAdT6VnXW155mDj5zkZoAyo9OhjlULId3qK0vIWGNQ25uM9OlPs0ImR8BsHJ96s3hjjRtqZYcE5oA5+4Rml4yM+tXrWxdlHlxs7djj9asW6GVyRtGBkHFWBPcJlYiVX8zQBXGlsrfvnVPr1qeO2s4+C5dvfgU7yHcBmDHPOaclsRwR+lAD/AC8riF48einFIljJLJlkBAPenPDHAu6XA9BVc3co/wBUSozx9KAH3sccHyjh/Tr/APqrnruKRnbeMg+nStv7SzA+Yobvmo5EjZGMbfMRjB4NAHNxSPCSMb4z1Q9D/hVxoUlhMkPzxfxoeqf59anltMscg5+lQhZLWUSJnjg/SgDOuLYp8yksnrjpTAuBxW9LED88Z+Vu3tVK4tVAJX7pGeKAKKbm6f8A6qlJEY+U5b+9/hUJ3fdxx6Udj2xQBIjgkAnk1s6VKMGJhlW/Q1z/ACDV7TpSsqc8ZFAGpJIY59ueM4xWfN8zHsc9+9XtRGHDoeQMGs6Rlbvg0AcZ4hUrq84PX5f/AEEUUniD/kLz/wDAf/QRRQB2bNjvUEjE5AJNSkBscYxx160woDQAqoXCcZPStS1twiNv+UAZd/T2FQ2EeDvwTtPH1qTVZPLtljjzknJ9zQBm6rfNKfKj+WJeij+vqaz0VmUH7vuac21Tk5ZqrySlSS5AHpQA+baAf4iOcmqDrtZ2fIA6D+8fSpWuFP3eap6gzFscYHJI9xQBBJIM/N1B5pA68cdagx3waF+8OKALIkJUYxUizsD2wO2KpocflUqKCQSKALyzjHIK579a0bW6je3KsRvPAYf1rGlwMDNLGcDIPOfWgDoYYWYdM4rd0W3QvuY7cEcgcGud0i5YAI/zKTj3BrstIjjaeNGKgMQB+dAGxc6Zc/2eHjy5OTwetYX2e8Mqh45M9Pu16C8YIjghdyyn5uw/zxWY8zy3LbQcA8cUAZFlptxxvX3x3qabT2eJ92NxPQc4+tdBa2jsk7EgyYCrntn0qRrHyUKtgEcnv+FAHK29k8UqEjIB/CtFrFQhbb17VqJFGMn+lWAUZMRx7iemaAMZLd8cBR+FTO5gXYqq8n0zirN15wAEahW7n0+lU1hmIyzEEnpQBRnhErF5YhkngkVUmtUJzGSv61vJ5qQ7X2svYMKoyqnmHehHvQBiy20iZBXI9RzVK5j4UDqeTXQtARlkbcOeO9Vbi1VyWZSGxQBiJKycN8wHr1FTjZKvy4z6VLPaMuSAGHqKrCFvMAThieooAsG3xBEUGCBjFU7xSsbAdjke3tW5bMsw2SDa4AAb1qpq9oQQB948/WgDlZFIbjpmkwCOaszJhuhzTNoPWgCDywByKfGCoBHapdgx3pQoxQBpXZ5P+HSsmVuD/hWtdjge4rMu02xk0AcVrh3apOf93/0EUU3WeNSm/D+QooA7kDFIeWqUIeCenqKkt7dpXRV5ZjjFAF3T7cvCpXsSSaoaud8oVR8qj8/eukeNYLABTtVQcsa5DWLnehCcJnn3oAyrudVJVMM3r2rLupC5UsSTj8qnuGGMVXETE4bKigBse1mGSR70k6OzMQpNSBVj7FiKfJIzjnjFAGeqENhh+NIVHVelWigZhtbOewprRry2TQBWAHfP5VNEB1GfxpNvzcVIgA4I5oAU7XfOMU90VG45phAVh6daljkxgHBAOaANvS4sKhAIOORXa+FYV+1xyOu4KM81y2koPIibByQD+FejeGIAIRLMoYsMAgYPFAGpETPbTvGTnOP15NXLS13yZdAqtxnNSf2OZiFtXaNwQcn0IroNE0gxTI1y2QgzjOaAJLXT0SNdyjA+bOPyrC1dCk7BVLBj+Vd9IsDRjggE561z9/FHI/yIBj8aAOTFqWwWOD6YzTktHLqEUtn0rfNip4K8AdqkjgIQsFIPagDL/syXcflUn0LDioX0yYrkJznNdHBbnsB7VM0DRxgBSx9qAOMu7F4VDOCCOuelY92NxAxjBx05rubq3MhPmLnjoaoyaRA+Dgq3qOlAHGrA4+bJBqzhWXEy8/3h1FbdxpjwgfJlB3AqvLakn7uewoAyWtR8xj+ZT3x+hqF9KA+fAWQjp2rYW2MLblJLfpUyBX4chZPfpQByM9uYn+ZcNSxsl2fIlJ3dI3rd1O3XaUIyT+lYM9oYhg5x2PpQBl6jYnDOow68MKyCgBHHNd1Mq3NpFcsMuf3UwHcjofxFcve2xhnkQ/wnH4etAGeYyOaQp27Vd8v5frTGTGMd6AJrkAqCB/XFZmp8IgA4zmti4XOBkfjWNqzZdcdh35oA4fWudSm/4D/6CKKTWf8AkJTfh/IUUAei7egx1rV0yApG0u352OxP64qii5k+ldJaxeX5C45RePqetAGN4mm8tYrRCNqcuR3Y/wCFcrcxtKDyNh6mt3VgXu5ZH6ZOBWVMu8ZY7VHXsKAMWSPymIAyemaik+UEswC+lWrycYIhGSP4j3rIkJblskmgB7zjoI8D1qqzv0Iyp9Kew9B1HWoyCfug4oAcnA55NPyfX2pFQkZyB+NOXr83NAB8x7DPbIpyudpyvHrip41AXOAc+vNWPKiyCy8HI9KAKZVdn+17VCyEHGfm6VopAAG7qpqxb2nnypgZB5OOtAGpoCvsiQZOeMV634WjcmKONVCKOSwzXFeF9JYHd5RbnHAyRXqGixC3mjUI+VGCMd6ANcITcLuAznnitzT7bLNkDAOBiqMEZdwwU5Jz0ro9Lg/docYyaAI3iBiUsmdo4x39q526ABZsDJY9eldvcopiICnp2Fc7e6ezSbnGFzwD1NAGMHYD5QuSOuKjUzbiNxx7Vtx2eeAmAfapxpiDlsgdOKAMNIpDgBm/OkaJ9+QW6YrohYREcbxj8aY+mNjKFWH1xQBhAzrGRuDKB0YZFRkqzYdNrZ7dK3X06RUPyFs9xzVRrMjqPzoAoR27Yyo3D6VFcWEUgO1djfpWqsDLkrnPsal2rIAHG00Acfc2LxlgV7duhrJuoSrH1rvbqDaGGMqep68ViXmmg5aMfgaAOUDEYjnwV7N6VDNafKwOGXr7VrXVqRkFcGqIdoDtk5jPXHOKAKVpalEnRjiN8YP0rE1+2K3KPxygB/Cu5ey8uAZAKN82R15rl9ahZHVDyVyc0AcyYzs9qiMZyvFabx5XpUQiJYZ4AoAr3iEYHBrE1XhxjjiuhvwN3HFYGqfeAHYUAcHrP/ISm/D+Qoo1n/kJz/UfyFFAHqlmmXXjvXWwxiOF5nHQZArntMg3zIo6dT9BXUaiUj02eWT/AFQIUD+lAHB6uQHdnPGT+Nc3dzvOMYG0ds9q1dZlaaUyNnB4A9KxGgd2yn3fWgCswU44wR3pjWplOVwvue9aSQR7Mj5n6EGlFsEUGT5E9e9AGaLaNByMt3z0qvLCzA7RnFac09uBiNCzdmNUWl83PJA9MYoAptEQMvhefWgFAOckirHlLJ1Jye55pn2Ug5GGoAWJozgFeMetX9PMdxKElVtuahSzDE7mUKBk4q7bWZjlO0EKDkGgB0vlw5J5PUcdfrWh4fMUlwCe3bFU2ih3HeGyeOK1dGsCFJjOSTzmgDutFuRDIvl8HP0r07woRdSAsokbHPGe1eRaRG6sFPTjk16r4MMsUoGMK5GD3xQB2iWEQzkHkYOMVfstiSbQh4wBxU0MZZkDYI9e9IIv3xOOQQAKALd6rCMogCjHWsWWItJzkg9zzW780kG3OfUVnyrj5QPxoAgihABBAz/SpmgUj5SMDpmmLGd2Gzn3q1HCpxuGPrQBAsCEjdg9+uak+yx7eCeasi2AwSOSecCpPIHPHagCobY7fkGR7VA8CtxIgzn0q88BQcZ9qiEko+UgOD/eoAy5NODA+X+RqlPalTtdMGumjWNzxwfQ02eEMpWRcg+tAHG7GjLADK9xTHgWQ5QYJ7V0N3p+MmP5hnoetZk9uVPyjkHn2oAwb2xWQncOfUdawrnTGXmQcDke9d0qq7Ylxv8A71Q3lmNrK4H40AclYorE2kmdr8Rk9j6Vg67Zl8yY+eM7G+ldLqdqYWLJnjkEeopuowiV2IHN1Duxj+LH+IoA81li2lhionjwRjpWrfRBWDY+tZ9xwuelAGfqCjP51yGuXGJcKcDFdJqkvyg9q4fXZv3r+gFAHPXzb7uRvU0VFKdzknvRQB7xpabLZ36M7BFP86n8VTFIrW0DHEancPVqfp6NstlA+6uT9TzVPXyRfSNJnf8Awj0oA5qeAciT/wDV9aoSIxJHCqvVuwrXnCIgeYsAegHVqxbzdc9wgHRR0oAqz3CoD9nwzd3x/KqswdsNI2SeeaeYyp5B4PapFt3mRA4KBehbrQBRbag4BzSKjMQMc+lXyEibb5e8/wB5hUnlFn4UAjmgDLa2PmAsQvP5UeSUGM5B569a2HtFEg8xlUelM8y0fMeGJHGV44oAgsdsTbmAI75710Qlhnjyw+Ydh/OuecgxuI0BXvu64rR0hJpBJmMoAcDFAF17FXw0TEq3bFdJp2l7LaEgHcRzjnFVdIjj3CKYkENkEf1rqoI9pCRnhRn6igCPTLGSOdSQWB4yB/nFep+G7YRojEHsBjtXL6GjuUAJ9PqK9M8OQKdilF54/wDr0Aa1uudpxgjirMUO+UEDB/nV+K2ULwDU8MIV9x554oAz5YDyRnH06VUNuxchl4x19a6Jx97gcDIqAruYZGSf1oAxUtt7fL1q7Da4BL4Jz09KtqoViMDGe1SqAT7UAQC3QgfJmlNqpUcEVcTBxwcU8Kpx1oAy5LEkcY/Gqr2rKSSpxnrXQmPg7SKhaI89M+uKAMB4Mj8aYA6HGNy46HtW7Jbqc5A/Cq8loccDI9BQBlvAHBKZ9dtUbm1DZyPxrYeFlLEHkUxlV+HGG9aAOVubNkfp+NVnlwBHKOOgaukvIjypArn761YAnqP5UAY+o25O5WGVI/OqN5btBDbg/wDLNQQa2ISJZFtpTkfwse3saXVIN8TRn7/8NAHlmuxBZpgBxuOK5u5Py112tKTcTZwCGIP4Vyl6hVjxx7UAc3rLfLk+9cBrc264cD8a7jXW2W0hPavO7tmeRmPc0AU2+9RQ/wB40UAfSWhQeaVc5CqB+PFYXiR1juZZ5Rln5RK7TSYltdOLMBtjj592xXnuttJeTtIecHgegNAGDJM80peRiWpRbll3dFNWhaqo3Hlx61bjRXGTjjrmgDLW1VeVHzep60yW3fHzDj371qPLGnEfzgd8YxVGXzm+8Mg9s9KAKkYiTh8t79aY4PLKQsft1FPkgGTliQf0pDFGUOPXtQBT+z8Fw5LN69qjW2Rc+acY9KvPCflwTgjqDR9mL4G0n1zQAzT7b95jcGQjOa6SxRJFG7jdxkdaq6RpbE4cEA/rXSXGktbQKuf3jD0+6PrQBFo0Lx3DMQGUdA1dDbOARGiKAx5bnI/GodAga0gVjGszvkEtzgV0djp4U7yAXPIxyKANLw/D5QHmFtxI6npXpGhOxkRRnPU4HWuN0G2MjYlGccg9uK7/AEOBRIjLzwelAHRQndgGpthLA5PFRQj5gT2q4o+Ye9AEb9MVXBPIHXFXWUYqDaCx46UAQKpyepqaNMDrxUqRc5AqZU+lADFTpTinA4qUADpRQBEV9qXBFSYFJjigCMgHtTSlSFBScgnGaAKssSsDms26gYEnGR3xWy2GJzwahlj5yRQBgMcDa4O31xVG9tyAeNwI475rduLXcMqAD14qgqGLKP8ANH3H933FAHK3VhsYkDgnn29qhun822MpJ3wnD/0NdTd2wVT0Kkdq5mWBo5bmA5KvGWz9DQB554kg2XDseBL8/wCPf9a4zUk2/SvS/EVoHs4yfvoxQ5/OvO9bjKZ4NAHn/iU5tJfQkfzrgZzye/PSvQPECZgkXrxmuAuOvTvQBSf7xoof71FAH1LeEpoYiXl5TnA6471ysluI93Gd3B9/auz1qPyLG3bGG2CuXu5I4ozJIMu33Uzj86AMK4tfs/zSZIP3RjlqqeTLK/y4VB/D/nrV66neT/Wnd/dPpVN5gnd8jvQBaj04sqn7mR1xxUh0xVTLSgE55x1qG0uJ5FKyBljxwxqY3WFzkAgfeI/zigCk9qhf95tVRxkjH6VA9tax5CFpGbv0FXJpfMbBO5cdh1+tVisYJ6Y/u0AQhUAG35ApqVGLhUT0zn1qtL5hf5Qqk9TipoY5tqqzsQehB4oA3tKt97eZLjA6DcBitO8uoruVYY2DMW/1aE9qwUgeODLSAKOrZ71v+HbZIF82QkSyH5c9celAHYaJppEKu8qE8celdBBaxKQgIK56dzn0rLiZsAQkiMLgjPNathFGyoS/HoaANnTbdGnDB2CL0QjpXd6HEoxjGcVxViPLkZATsz6da7nRgoUHJJI70AaaoQeO5qYK24ZoXHAz36VJQA0hcYzTUAHQYzTzgn3poOBmgB+BS5qIOSTUo6UAFFFFABRRRQAUhGaWigCKRRzxUfI4PK+lWaYyZPGKAK0iBlypz/SqVzErKd34EVfkBTnvVaUiQccOO3rQBiSOI3MUn+rbp7e9Z09r88wPZDg1sX0O4Hf/APXFV0jzZsjH5gMg+ooA8+1tP9GkUjDBxx74rzvxDDgMcZzXqfiy3/0RGXP+sG4j9K8511GKvnp0zigDyvWEDORnOOted6jH5U0iHsa9Q1GEb34NcD4kg2TK4H3hg8UAc0/3jRRJ980UAfW/ifbHpVvNKMqowB6ntXnE0jyXDO2Dv/SvRPGv722hteBtTP1Oa4dLQMC7nC/zoArRwPL8oXOeuRSSWQVcYDSDJB7VpxYHyDHTgdjTJVwMtwCMdaAMmGFt7Fj82PrTLpEMfzAj6VckljRmTnIGBtHP0NZU8zANuGMnoKAI3L7RsICEU1Y2AJZgfpUMx3HG0gDnApqzsGVVJBx07UATqpeQNIygdMVMkjNKFjdVUDJOPT0qGJXkPzjk9DUs0LRxqRg5PzH2oAsaaGuL0ISTEDkgjg4r0PTLASMszD5FHT1Ncj4Xs9zlmKfNg8849q9Q01IIoolALOfUcUAQzHyWRdpyx4wK29NJjjy4yQM9OaaoM0uG2qidTjBqeCPa4UtnPP1oA0dK3zzKzEDJBAr0LSYwirjrjn3rhdIBE4YAq2cdK9A0vLQg7MnoTQBfXINSc8dKAOOgpaAExTGQk8GpKKAIwnJqQDAoooAKKKKACiiigAooooAKKDTGYg0ANl5zmqM0RAyv/wBcVeZgcZGDUEg5wKAKRX7QcMBuHU+tVZU2yr9cfStGRcZZeGFVbkh4y+OR94UAclrdsHnmiYcbSB9eo/WvMtehGxuDXruuRYuY5cZPAI+teZeIYsSSp6EjH40AeT6nDtd/auF8SQb4ZMDleRXpetxASOAOtcLrEQ+agDzWX/WHNFPvE8u6lT0YiigD6116ETXpZifLUc//AFq5nUotsm9B8rdl7Guu1pVU+Weqn5jXN6lIkERQrlmHQ9FFAGHNIqIFb7w6AdqryztIq7uW5+b+lRXWY3BZ8dxnvTDkMMMGB5OaAGiLcd6E788/SmzRxOO4OeFPSr1uVRT8wyw6D+tK9seJJzu3dAOMUAY7WTSAiPO4fez0zTY7AJwzgt1OP5VtTr+7CQqSB6cYp0dh5cLSTL82MZFAGH5Y34Vee2ev1pGXagQguWOTn1zVyVzHOW2KNo+92PtWRPcTSXIjZvl6gAdqAO48PxxAKpIQLjODmuvtri3UbVkfcq5J25FcJ4aQcCNcZOSx78V2en2jRzeW6kZwSfzoA6jT2ha1RgxZjzz/ACq5ZOjy8xk5+UE+tZ1nJb2rqzK7qODtODj27Z+tXrR0zkPiM8jPX8aAOp0tolK4QAgYB712emgeXHs+6B0rgtLAaRSMkE8fWvQtNAFunrgUAW6KKKACiiigAooooAKKKKACiiigAooooAD0qNx3xUlFAFdl55poIHBqZ19PyqrKODgUAJOMdOtUJB+94J+bhhVsy8FG6djULLtmzjhRmgDJ1JA1wyNnB4/GvNPECfvpz33nP516jqQVXWTPG3Oa858Sx7Z5x/tk/wCfzoA8t1hPnzjnmuG1mMc4Fega4BuOAeprhdZ75oA8q1UY1G4H+2aKXV/+Qpdf9dDRQB9beJZBb3jzuCY1AbH97PauKvJXmJkL5DHmuy8dqRBa49Nzf0rhnbYWB5B7e/tQBVljD8E7UPc9vpTFgeOYncAh4LEZ3D6VejhYsA2Ce3PAFOd1QMrDce/oPpQAy1ihib+J9w6D+dQXUxjJDr04GetJLMyMGUg4GAPQetUL+7k7vuJ6UAWzehNpVPnPoeh/xqK/1CaVPLXhMfl+NZKMWcNwGFNnnOWYgDP3f8aAK5dkZ43JKkEEk0wr5bhiMsD19qhlmBYMT9Ae9StKrRgZAY9ff6UAdZoDASplSQeDk/yr0TTl8y3M27Jz3715to58xbYKRyBwK9R0ouljuSNQqnHzf4UATRnlNxGMZPv9K0dOdZGKBMKTgD0rOFsC4kBZ1/hA4z61vaTafdb5VHFAG5okDGQZHIPA9a9C08YgXnsK43T8ouRjeOAR612On58kZHzYGaALVFFFABRRRQAUUUUAFFFFABRRRQAUUUUABOOtIGBPWgnr2qNyc9RQArtg1BIdwzT2b1qOTJHFAFOZDux1zTiwMRQ9cVMVxn361RmYxzjJ+UjvQBQ1skadGRnKnt6VwXiU5uJfQ4P5gV32qNuSNMDDKfyNefeJMm5kx1wP5UAeaa2MSN9TXCa31au610jzOD3rgtbJywz+VAHlur/8hO6/66Gik1X/AJCVz/vmigD678XESTgMMqE21xFxB5AZZMbxz612+u7JLvzGI2gEj61x+pp5mdp+Yc/UUAZLTNGQmMKaga43sfL6KOWPf2qG6uGztjGU7mqkkm1duQxPXHagCwZtzKiD3znmoNTAVIwQfMAySKhSUKS20VHG7TOcdM5OaAJEIhiR9oDH16Vm3czyzfOQ3cAcZq1dyGTIHJPGarrZhmAPcdB60AUPLeR2G0/Lg1OsO9UycZPT2q4LZtxiiUuw5O0GtGDRrl9uYX+bjGMZ/OgDa8G25jikKheDgN6V6FYT5VldlEUeAoJwDx1rkdP0y5gs1TyxBGSMlecn61eFrKkqB5Cyt94GgDsbK4gMpjMiZT5uMmum0J4xuBXzCeenFcrZ2oQxOFwwALEnqK6jSdscezZweSwNAHSWk6mRAka8ccCut09g0XHXvXJ2SKqgoM565rqdMKiFQOpoAu0UUUAFFFFABRRRQAUUUUAFFFFABRRRQA1uh4ph5NS1GynPHNAEMgHeoS+M8cfzqaQe1VpSADQA+RgV4rPvUMqFAOexp0kpU5GeOo9aUFW/eLyMflQBmamcfZz2UbTXAeK3231wAMYYiu+1Uj7Or8bd3JrzrxZJm5mY8Fvm/SgDzjXWBkzXn+tvgnmu41lxuYZ9a8+1uQDeT2BNAHnep/8AIQuO/wA5oqO7bdcyt6sTRQB9Z65IR5IzkOmfxrkdXutu5FPPUnPQVva1cg2EM5+6ikGuEmufPZi5APegCOcscyLg85KjoT7VS3qASeGPY9quSZYhVBz/AAgetXrPQJbmRXnBBJ5A6H60Ac6DJPJiNGY5wAK2tN0K6upFWYmFc8kLmu40jw1HHszHtwOhHWuptdJVAx8s8jC8dKAOD07wZBJKFcPIDyWycV0dl4St4UZUjRP9rblq66ztRbMuBjt0q2kDOwypHpmgDmrTw7bwBdi5fHU9v8alt9FjVy+z5jxubJzXZRWUflozDjpgdaU2uRnkD+lAHKXNiXRSD8qAYGOD9Kh/s0D52wTjgHrXXzWYVQoUbSOfU1Wn08Y4yAO3pQBlWEbR22/GWLYrbthH5KnkMDg+4qtHbEROFG0jB+tX40CIA42sDnjvQBetphnqR9a6rRJmkQAgZ7muYskBYZUGMjrXT6NH5QJx8vagDYooByM0UAFFFFABRRRQAUUUUAFFFFABRRSbhntQAtIxxTHbGaYz5oAbPyOKz5iP4uvvV2Q/Wqcw8wHkgHvQBUlG7GM5xyaYknlOUY4VuPoanlJQY6H6Vl3kpXLE4A60AQayzDT5E778j8BzXmniub97ITycD+VeharcBo7ZicCRT+teV+Krg+fMGPIOOvpQBwmsS/fIrzjxPcBVYA8122vXSxxsS3zenpXlmvXZlnK5PFAGHJy5oof7xzRQB7te6q/9ixwytne3X6ev41gG4V8kfe7CrNyPtFrbrgcoT+OayxbTW14rEFox0HvQB2Wg6f5m15MGRuvtXo+jaWqxqzrn0z1rifC0qsVLkAKeAa9M06ZCoOcY96ANCysh6DPrWgLUYwBwKLd027Rg/jV9U3ADHQdqAKMdszsCfujsauw2zA8dPSrkcAXHGBVlVU+w4xQBXhtvl5A45pZIcsCe/ABq0cYPzY9c8cUjNGQNpLHHb/GgCs8OQOBkdMU02pLfOFA9PWr0Ydo+AEHr3NOWEBic/ieTQBnR2rM3yjn1NSw6dtOWzyeQa04mEYwijJ7mneU0oyxP40AQ2dsqHkKcdADW5aA/Ljp2rPhi2Y/TitO2yBnoMUAWx0ooHNFABRRRQAUUUUAFFFFAAaaGHrihmxUJ570ATM2KjLc1C7FfunFRfaMH5higCwzcGoXbBPtTTKCCRzTGOeaAFaTPB6UxjwahlcKMmoWuUHyluexoAS8bKkjqO1c/fTF22rgc/wCTWleTgA84zXNajdLE7N1LDigBNQmDQxY42vt69BXkfjTUEjvLraQT5jd+2a6/XNcEFixzhjKVA/CvDvGGtGW/uBGd2XNAGJ4k1Pg4OWPauGuGLOSxBJ61qajIzvljlu5rJcZfnjPP1oAgf7xopZgBIQOnFFAHrluf3EP0P860JBmPnniiigDZ04DavA6Cus0iRw6AMwHpmiigDsNMYlzknoO9b8LHaOTRRQBfhJO3J7Uy4dgcBiBkdDRRQBFESz/Mc8d62IgPSiigDQwPKXiq55Zc0UUAWIwNy8Cpk70UUAPX7w+lWoO1FFAF8dBRRRQAUUUUAFJ2oooAUU1ugoooAYeahPUUUUARy9DVSX+tFFAGe5KzvtJHParSkkDJNFFAFS5J2jk1lXbMF4Yj8aKKAKd4x29T+dcx4kZhBwSPx+tFFAHk3i+RzFbAu2C7ZGfevNdY/wCPqYdtxoooA5i+/i+lZx60UUARyfe/KiiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph 12 hours after a left pleuropneumonectomy demonstrates a tension hemothorax. The postpneumonectomy space is completely opacified, with contralateral shifting of the mediastinum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Irwin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_23_41342=[""].join("\n");
var outline_f40_23_41342=null;
var title_f40_23_41343="Cautery of epistaxis with a silver nitrate stick";
var content_f40_23_41343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cautery of epistaxis with a silver nitrate stick",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The silver nitrate applicator tip should be applied to a small area surrounding the bleeding site, starting proximally. The bleeding point itself cannot be cauterized until hemostasis is achieved through proximal cautery, vasoconstrictive agents, or direct pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_23_41343=[""].join("\n");
var outline_f40_23_41343=null;
